HSBC Life Assurance (Malta) Ltd

Solvency and Financial Condition Report

2021

Coı	ntents	Page
Sur	mmary	3
A.	Business and performance	5
В.	System of Governance	11
C.	Risk profile	35
D.	Valuation for solvency purposes	46
E.	Capital management	59
F.	Appendix I: Quantitative reporting templates ("QRTs")	65

### **Summary**

HSBC Life Assurance (Malta) Ltd ("the Company") is authorised to carry on the business of insurance by the Malta Financial Services Authority ("the MFSA") in terms of the Insurance Business Act, 1998 (Chapter 403, Laws of Malta). The principal activity of the Company is to carry on long term business of insurance in and from Malta.

The Company was granted rights to provide services under the Freedom of Services Legislation in terms of the European Passporting Rights in several European countries and is also licensed to offer business of insurance in Jersey, Channel Islands.

The Company has an established system of governance in place, including the Board of Directors ("Board") as well as a number of Board and Business Management Committees, which contribute to the sound and prudent management of the Company.

The Solvency Capital Requirement ("SCR") coverage ratio as at 31 December 2021 position was 208%, with own funds of €58.2m and a SCR of €28.0m.

The objective of the business' capital management strategy is to maintain sufficient own funds to cover the SCR and Minimum Capital Requirement ("MCR") with an appropriate buffer. The Company currently maintains a high solvency ratio to ensure policyholder obligations can be met under stressed conditions and also to support the financial strain from new business initiatives.

The Company carries out regular review of the solvency ratio as part of the Company's risk monitoring and capital management system. No material changes to the Company's risk profile were reported during Financial Year ("FY") 31 December 2021.

The Solvency and Financial Condition Report ("SFCR") has been prepared to satisfy the requirements of Article 365-370 of the EU Commission Delegated Regulation 2015/35 ("CDR") and Articles 51 & 53 to 55 of the Solvency II Directive 2009/138/EC ("Solvency II Directive").

This document aims to provide the information required in accordance with Article 365 of the Solvency II Commission Delegated Regulation. In line with this, the document contains information on the Company's system of governance, business, valuation principles, risk profile and capital structure.

Statement of Directors' responsibilities in respect of the Solvency and Financial Condition Report ("SFCR")

The Directors are responsible for ensuring the SFCR has been properly prepared in all material respects in accordance with the Malta Financial Services Authority ("the MFSA") rules and Solvency II Regulations.

The Directors are required to ensure that the Company has a written policy in place (Reporting and Disclosure Policy) to ensure the ongoing appropriateness of any information disclosed and the MFSA

(a) throughout the financial year, the Company has complied in all material respects with the requirements of the MFSA rules and Solvency II Regulations as applicable to the Company; and

(b) it is reasonable to believe that, at the date of the publication of the SFCR, the Company has continued so to comply, and will continue to comply in future.

The SFCR was approved by the Board of Directors on 28 March 2022 and was signed on its behalf by:

Muriel Rutland

Director of HSBC Life Assurance (Malta) Ltd

expects that the Directors should be satisfied that:

Date: 28 March 2022

# A. Business and performance

#### A.1 Business

## A.1.1 The name and legal form of the undertaking

The Company is a limited liability company domiciled and incorporated in Malta. Its registered office is:

80 Mill Street Qormi QRM 3101 Malta

## A.1.2 Financial supervision

The Company is authorised by the Malta Financial Services Authority ("the MFSA"). The registered offices are as follows:

Malta Financial Services Authority
Triq 1-Imdina Zone 1, Central Business District,
Birkirkara, CBD 1010
Malta

As the Company does not form part of an insurance group, it is treated as a solo legal entity for Solvency II reporting purposes. Therefore, insurance group supervision is not applicable.

## A.1.3 External auditor

PricewaterhouseCoopers is the Company's auditor for the financial year commencing 1 January 2021. The auditor's contact details are as follows:

PricewaterhouseCoopers 78, Mill Street Qormi QRM 3101 Malta

#### A.1.4 Ownership and group structure

The Company is a wholly owned subsidiary of HSBC Bank Malta p.l.c., the registered address of which is 116, Archbishop Street, Valletta, Malta.

The Company's ultimate parent Company is HSBC Holdings p.l.c., the registered office of which is 8, Canada Square, London E14 5HQ, United Kingdom.

The proportion of ownership interest held in the Company by HSBC Holdings p.l.c. is 70.03% and HSBC Bank Malta p.l.c. ("HBMT") is 100%. The proportion of voting rights is the same.

# A.1.5 Principal business activities

The Company is authorised to carry on the business of insurance by the MFSA, regulated by the Insurance Business Act, Cap 403. The principal activity of the Company is to carry on long term business of insurance in and from Malta.

The Company was granted rights to provide services under the Freedom of Services Legislation in terms of the European Passporting Rights in several European countries and is also licensed to offer business of insurance in Jersey, Channel Islands.

## A.1.6 Material lines of business and material geographical areas where the insurer carries out business

The Company's primary business is to carry on the business of long term business of insurance in and from Malta. The operations are restricted to Class I Life and Annuity and Class III Linked long term insurance.

On 30 November 2014, the Company completed a Portfolio Transfer Transaction with HSBC Life (Europe) Limited ("HLE"), a subsidiary of HSBC Holdings p.l.c., based in Ireland. The Company acquired the insurance and investment policy book of HLE, consisting mainly of unit-linked investment policies sold across the European Union ("EU") under the Freedom of Services provisions. The portfolio also includes a closed book of life protection business. A part of the portfolio was transferred to a European insurer in December 2018.

The Company's main lines of business are split into the following Solvency II lines of business:

- Insurance with Profit Participation
- Index-linked and Unit-Linked insurance
- Other Life Insurance

Further details on the classification and types of insurance contracts underwritten by the Company can be found in Note 3.1 of the Company's 2021 Annual Report ("Audited Financial Statements"). The Company prepares its Financial Statements in accordance with International Financial Reporting Standards ("IFRSs").

On 7 December 2018, the Company transferred a group of policies forming part of the Wealth Insurance Italy portfolio to Lombard International Assurance S.A., in line with the Portfolio Transfer Agreement entered into on 9 November 2017. This portfolio formed part of a larger portfolio which was acquired in 2014. This transaction will not have a significant impact on future years' profits, Own Funds and SCR.

# A.1.7 Significant events

In 2021 the Company has continued to focus on its core business of serving customers' protection needs, and in supporting them to plan for their future and their retirement. Throughout the prolonged Covid 19 situation, the Company has successfully implemented business continuity responses and continued to maintain the majority of service levels.

During 2021, given the outlook for continued low interest rates and the high capital demands of providing capital guarantees it was decided to stop new business sales of the With-Profits products.

Overall the balance sheet and liquidity of the Company have remained strong.

The Company reported Solvency II ratio for 2021 of 208%, compared to 181% registered in the prior year. This positive variance of 27 points was primarily driven by the tax agreement signed between the Company and its parent' Company which gives the Company the ability to fully recognise the loss

absorbing capacity of Deferred Taxes in the Solvency Requirement Calculation partially offset by the categorisation of the cash position held with unrated counterparties.

# A.1.8 Performance of other activities

The Company does not have any financial or operational leasing arrangements in place.

# A.2 Underwriting performance

# A.2.1 Analysis of underwriting performance

The breakdown of the underwriting performance of the Company as at 31 December 2021 and 2020 by the Solvency II line of business is provided in the tables below:

	Insurance profit part		Index-lir unit-link insuranc	ed		Other life insurance		Total	
	2021	2020	2021	2020	2021	2020	2021	2020	
	€′000	€′000	€′000	€′000	€′000	€′000	€′000	€′000	
Premiums written									
Gross	13,461	14,992	35,775	33,824	14,858	14,731	64,094	63,547	
Reinsurers' share	-	-	-	-	5,738	5,420	5,738	5,420	
Net	13,461	14,992	35,775	33,824	9,120	9,311	58,356	58,127	
Claims incurred									
Gross	27,408	28,591	38,775	30,732	2,683	4,360	68,866	63,682	
Reinsurers' share	-	-	-	-	2,097	3,246	2,097	3,246	
Net	27,408	28,591	38,775	30,732	586	1,114	66,769	60,436	
Changes in other technical provisions									
Gross	-12,058	2,114	35,704	17,568	-1,196	3,770	22,450	23,452	
Reinsurers' share	-	-	-	-	-1,760	2,581	-1,760	2,581	
Net	-12,058	2,114	35,704	17,568	564	1,189	24,210	20,871	
Total expenses incurred	1,283	1,255	3,007	3,727	4,209	3,404	8,499	8,386	

The explanation of the differences seen as at 31 December 2021 and 2020 is summarised below:

- Increase in unit-linked product and good performance of protection partially offset by the decrease in gross written premium for Insurance with profit participation is due to the decision to stop selling this product. The increase in claims incurred for the Index-linked and unit-linked insurance is mainly due to higher maturities, surrenders and claims of the investment products, particularly in relation to the attrition of the acquired portfolio.
- The changes in other technical provisions for index-linked and unit-linked insurance include the movements of the value of the policies representing the change in the value of the underlying assets.

• Actual expenses controlled and stable over the period.

## A.3 Investment performance

# A.3.1 Analysis of investment performance

The Company invests in a variety of asset classes, namely bonds, equities and investment funds, cash and deposits and property. These investments are either assets held for index-linked and unit-linked funds or investments held to back up insurance liabilities as well as shareholders' funds.

The investment returns as at as at 31 December 2021 and 2020 is summarised by asset type below:

2021 €′000	Bonds (including structured notes)	Equities (including investment funds)	Cash and deposits	Mortgages and Loans	Property	Derivati ves	Total
Dividends	-	8,910		-	-	-	8,910
Interest	945	-	19	-	-	-	964
Rent	-	-		-	1	-	1
Realised/unrealised gains and losses	-2,737	36,502	454	-	-	-	34,219
Total	-1,792	45,412	473	-	1	-	44,094

2020 €'000	Bonds (including structured notes)	Equities (including investment funds)	Cash and deposits	Mortgages and Loans	Property	Derivati ves	Total
Dividends	-	4,058		-	-	-	4,058
Interest	944	-	19	-	-	-	963
Rent	-	-		-	10	-	10
Realised/unrealised gains and losses	4,475	12,599	(455)	-	(599)	-	9,178
Total	5,419	16,658	(436)	-	(589)	-	12,264

The higher investment returns in 2021, against 2020 was largely the result of market value movements of investments underlying the unit-linked business, which does not have a direct impact on the profits of the Company albeit an indirect impact through higher Annual Management Charges ("AMC") revenue. All unit-linked gains or losses are offset by an equal movement in policyholders' liabilities.

# A.3.2 Information on gains and losses recognised directly in equity

The Company did not recognise any gains and losses directly in equity.

#### A.3.3 Information on investments in securitisation

The Company does not have any investments in securitisations.

## A.4 Performance of other activities

# A.4.1 Other material income and expenses

The comparison of other material income and expenses between 31 December 2021 and 2020 are presented in the table below:

Investment Contract Fee Income	2021	2020
Investment Contract Fee Income	€′000	€′000
Fixed fees, change in deferred income and annual management charges on transferred portfolio	1,389	1,189

Investment contracts fee income comprise of fixed fees and the change in deferred income relating to commission income from fund management based fees and front end fees. The increase over 2021 is mainly due to higher revenue from the annual management charges on portfolios which experienced a higher Fair Market Value.

# A.5 Any other information

There is no other material information regarding business and performance that has not been disclosed in sections A.1 to A.4 above.

### **B. System of Governance**

### **B.1** General Information on the system of governance

# B.1.1 Structure of the administrative, management or supervisory body

The Board of Directors represents the Company's administrative, management and supervisory body ("Board"). The Board is the focal point of the governance system and is ultimately accountable and responsible for the Company's risk appetite, strategy and performance.

The Board and Management have a statutory responsibility to manage risk and capital requirements to prevailing regulatory and Solvency II standards, encompassing any outsourced suppliers or support functions that provide services to the Company.

At the time of publication of this report, the Board consisted of seven directors<sup>1</sup>. Board meetings are held at least quarterly in Malta, with all members being invited. The quorum necessary for the transaction of business shall be such that the number of directors constitute a majority of the Board. The majority of the members would constitute 50% plus one of the total members.

It is the Board's responsibility to review the Company's overall strategy, business planning processes and the performance of Key Functions. In addition, the Board is responsible for the approval of the Company's Board policies and the approval of the persons responsible for Key Functions and deemed as critical for the Company, in line with Solvency II requirements. Furthermore, the Board is responsible for the approval of the Financial Resources Plan ("FRP"), the Audited Financial Statements, the Solvency and Financial Condition Report, the Regular Supervisory Report, the Actuarial Function Report and the Annual Quantitative Reporting Templates and National Statistics Templates.

The Committee structure of the Company comprises of the Board, the Audit and Risk Committee and a number of other Management Committees, with the main purpose of:


- (a) maintaining high standards of corporate governance;
- (b) running the business in an efficient and effective manner; and
- (c) aligning the Company's governance structures to the risks they carry.

The Board also acts as the Company's Remuneration and Nomination Committee in line with Solvency II requirements.

\_

<sup>&</sup>lt;sup>1</sup> One Director pending regulatory approval.

The Company's Committee structure is presented in the diagram below:



The HSBC Group Mandatory Committees and Forums have been outlined in red, local Regulatory requirement have been outlined in blue

#### **B.1.1.1 Board Committees**

The Audit and Risk Committee meets at least quarterly and acts on the Board's behalf with the primary purpose of protecting the interests of the Company's shareholders and customers. The Committee is accountable to the Board and has a non-executive responsibility for oversight and advice to the Board regarding financial reporting, high level risk related matters and governance.

### **B.1.1.2** Business Management Committees

- (1) The Executive Management Committee ("EXCO") meets at least six times a year and operates as a direct management committee under authority of the Board and is responsible for the oversight of the Company's day-to-day operations and performance and for the overall delivery of Insurance strategy and implementation of priorities as approved by the Board, taking into consideration the input from Group Insurance, Wealth and Personal Banking (WPB), Commercial Banking (CMB) and Senior Management. The Parent Committee of the EXCO is the Board of Directors. The sub-committees of EXCO are the i) Asset & Liabilities Management Committee, ii) Product and Distribution Committee and iii) IFRS 17 Steering Committee.
- The Risk Management Meeting ("RMM") meets at least nine times a year and is a meeting convened specifically in respect of matters concerning risks within, or impacting the Company's business and performance, including the monitoring of the adequacy and effectiveness of the Company's Risk Management Framework. The RMM is established to provide recommendations and advice, as requested, to the Head of the Risk Function in the exercise of his/her powers, authorities and discretions in relation to the enterprise-wide management of all risks, and to the policies and guidelines such as the internal HSBC Group policies (IFIM) for the management of such risks. The Parent Committee of the RMM is the Audit and Risk Committee. The sub-

committees / forums of RMM are the i) Financial Crime Compliance Forum which has the primary responsibility for the oversight of FCC risks and issues, ii) Risk and Control Forum which has the primary responsibility of overseeing the adherence to the Group Operational Risk Management Framework and iii) Model Oversight Forum which supports the CRO in discharging their responsibility as the Risk Steward for Model Risks and iv) The Third Party Governance Forum which oversees all third party contractual arrangements and v) Data Quality Forum which has the primary responsibility for overseeing the implementation of the Company's Data Quality Guidelines.

- (3) The Asset and Liabilities Management Committee's ("ALCO") meets at least six times a year and its primary responsibility is to report to and advise the EXCO on all matters pertaining to the balance sheet and investment of insurance monies. The ALCO is also responsible for the management of balance sheet assets, associated risks and earnings (including adherence to economic and regulatory capital requirements) to achieve performance objectives within prescribed risk parameters. ALCO is responsible to report on the compliance with the Solvency II Directive as directed by Article 132 'Prudent Person Principle' of Directive 2009/138/EC. ALCO should consider and manage conduct risks and ensure positive customer outcomes. The subcommittees of ALCO are i) Investment Forum ("IF") whose primary responsibility is to monitor performance of appointed asset managers and provide recommendations to ALCO ii) Actuarial Control Committee ("ACC") whose primary responsibilities is to support the Head of Insurance Finance and Chief Actuary to ensure appropriate governance and control exists for the use of actuarial judgement impacting IFRS, Economic Capital, and local regulatory solvency. ACC's decision requiring ratification should be escalated to local ALCO. ALCO is an advisory committee to support the Head of Insurance Finance's individual accountability for ALCO issues. The Head of Insurance Finance chairs the ALCO and is the executive accountable for ALCO issues and ALCO decisions. The Parent Committee of the ALCO is Insurance Executive Committee (EXCO).
- (4) The IFRS17 Steering Committee was established in 2019 to provide oversight and implementation of the new accounting legislation. It meets at least ten times a year and its primary responsibility is the successful implementation of the IFRS17 project. The steering Committee reports directly into EXCO but also provides direct updates to the Audit & Risk Committee and Board.
- (5) In 2020, the Company established a Products and Distribution Committee ("PDC") which has the primary responsibility of reviewing the existing product range and proposing new products and variations. This committee will also escalate any issues related to the Product Approval Process to the EXCO as the parent committee, and EXCO will in turn escalate any unresolved issues related to the Product Approval Process to the Board. In some circumstances, Products and Distribution Committee is to seek Board Approval.

#### **B.1.1.3** Risk Management

The Company has a risk management policy designed to enable the Company to:

- (a) understand and manage the most significant risks faced by the Company;
- (b) take effective decisions around business opportunities; and
- (c) determine the allocation of risk-based capital.

It is based on the 'Three Lines of Defence Model' and is integrated into the Company's organisational structure and decision-making processes. Its main objective is to identify, measure, monitor, manage and report on the inherent risks in order to safeguard the interests of shareholders, customers and staff whilst achieving the Company's commercial objectives.

#### **B.1.1.4** The Three Lines of Defence Model

- First Line of Defence (FLOD): The FLOD has ultimate ownership for risk, including understanding all conduct risks and managing the controls. This is provided by Management and staff who are responsible for the day to day identification, management, control and reporting of risk exposures. Risk exposures are monitored against risk appetite and risk tolerance limits, and key performance indicators, set by the Company. Stress and scenario testing are also performed to assess the adequacy of mitigation plans in place. Key risk issues are reported to the RMM, the EXCO, the Audit and Risk Committee and, ultimately, to the Board. The Actuarial Function also forms part of the first line of defence.
- Second Line of Defence (SLOD): The SLOD reviews and challenges the FLOD's activities to help ensure that risk management decisions and actions are appropriate, within risk appetite and ensure that conduct risk is adequately considered in all revelant financial and non financial risks types. The SLOD is independent of the risk-taking activities undertaken by the FLOD and includes the Risk Management Function, Risk Stewards and the Group Operational and Resilience (ORR) Risk Function. The Risk Stewards are subject matter experts who set policies and oversee the FLOD activities by risk type. The Compliance Function who are also Risk Stewards forms part of the second line of defence.
- Third Line of Defence: This comprises of the Internal Audit Function which provides independent
  assurance to management and to the Board with respect to the design and operation of the Risk
  Management, Governance and Internal Control processes.


External Audit and the Audit and Risk Committee provide additional oversight and challenge with direct reporting to the Board.

# **B.1.1.5** Key / Critical Functions

The Company has established the four Key Functions required under Solvency II, namely the Actuarial, Compliance, Risk Management and Internal Audit Functions.

None of the key functions are carried out directly by the Board, but instead they are entrusted to Key Function holders who all have direct reporting lines to the Board.

The Company's reporting lines of the Key Function holders are illustrated in the diagram below:



A description of the roles and responsibilities of the key functions is presented below:

#### (1) Actuarial Function:

The Actuarial Function is outsourced to HSBC Group and headed by the appointed Chief Actuary who reports into the Regional Chief Actuary. The Chief Actuary currently has a direct reporting line to the Board and his responsibilities include, but are not limited to, the determination of the technical provisions that are held on the Company's balance sheet and the calculation of the Solvency Capital Requirement ("SCR"). The Chief Actuary is also responsible for the oversight of duties in relation to key risk management and risk mitigation processes, including data accuracy, claims management processes, underwriting processes and reinsurance arrangements in place. The Company's Head of the Risk Function and subsequently a non-executive Director were designated as the person responsible for the oversight of the outsourced Actuarial Function until 30 August 2021 and 16 February 2022 respectively. This role is currently vacant and the Company is in the process of identifying the new Actuarial Outsourcing Monitoring Officer.

# (2) Compliance Function:

The Compliance Function comprises of both the Financial Crime and the Regulatory Compliance functions which are led by the Compliance Advisory Manager acting both as Compliance Officer and MLRO and is responsible for advising the Company's Board, Management and relevant personnel on compliance matters, including requirements imposed by insurance legislation, as well as company-specific provisions adopted in order to comply with the Solvency II Directive and other applicable laws and regulations. The Compliance Officer also provides an assessment of possible impacts of any changes in the regulatory environment and how these are expected to effect the operations of the Company. The Compliance Function is responsible in proposing and implementing the Compliance Plan.

# (3) Risk Management Function ("RMF"):

The Head of Risk Function heads the RMF and leads the Company in monitoring risks faced by the Company and ensures that appropriate actions are identified and taken in the case of any potential or actual risks faced by the Company. The Head of Risk Function is also accountable for ensuring that the business operates within its agreed risk appetite and risk tolerance limits, and that an effective Risk Management Framework, which is aligned to HSBC Group Policies and industry best practice, is in place. The preparation of the annual Own Risk and Solvency Assessment ("ORSA") Report and the implementation of the Risk Management Policy also fall under the Head of Risk Function's responsibility.

The Head of Risk Function is explicitly accountable to the Board and its Committees with respect to the monitoring of the adequacy and effectiveness of the Company's Risk Management System. A Non-Executive Director has been designated as the person responsible for the oversight of the Risk Management Function on behalf of the Board.

## (4) Internal Audit Function:

The Company's Internal Audit Function is outsourced to the Internal Audit Function of HBMT and is supported by the HSBC Group Audit team. The Internal Audit Function provides independent assurance to the Board and the Company's Audit and Risk Committee with respect to the effectiveness of the Company's risk management, governance and internal control processes. It enables the Company's Management to accomplish its objectives by providing an independent, objective and constructive view of the Company's processes. The Internal Audit Function is accountable for proposing and implementing a risk-based Audit Plan and programme of work, which is approved by the Audit and Risk Committee on an annual basis, covering key risks, emerging risks, horizon risks and regulatory obligations. The Company's Audit and Risk Committee has been designated as the body responsible for the oversight of the independence and performance of the Internal Audit Function.

In addition to the Key Functions under Solvency II, the Company considers the following functions as important/critical:

- Finance
- Operations
- Underwriting & Claims
- Investments
- Money Laundering and Financing Terrorism
- Products and Distribution

As per the Insurance Rules Chapter 1: The Application Process and Chapter 2: Fit and Proper, an Insurance Undertaking is required to appoint a member of the Board of Directors and a person within the management structure of the Insurance Undertaking who will be responsible for the oversight of the insurance distribution activities. These two roles are filled by the Company CEO and the Company's Head of Products & Distribution respectively. The Distribution Oversight Director has the responsibility to notify the Board with any new, changes, challenges and concerns on the distribution of its products. This responsibility will be discharged through a regular PDC update to the Board, that will cover all new products, product changes, as well as issues in relation to product distribution and other ad-hoc updates.

# **B.1.2** Material changes in the system of governance

The table below presents the Directors resignations and appointments which took place from 1 January 2021 up to 15 March 2022:

Resignations	Appointments
<ul> <li>Joyce Grech – 20/1/2022</li> <li>Harpal Karlcut – 16/2/2022</li> </ul>	<ul> <li>Charlotte Cilia – 20/1/2022</li> <li>Phil Blackmore – 16/2/2022 subject to Regulatory approval</li> </ul>

#### **B.1.3 Remuneration Policy**

The Company's Remuneration Policy is designed to reward competitively the achievement of long-term sustainable performance, attract and motivate the very best people who are committed to maintaining a long-term career with the Company.

This policy is a supplement to HBMT's Remuneration Policy and covers the principles and standards specific to the Company in relation to remuneration awards and arrangements in addition to HBMT's Remuneration Policy.

The scope of the Company's Remuneration Policy is to ensure that its remuneration standards and arrangements promote sound and effective risk management and not to encourage risk-taking that exceeds the risk tolerance limits of the Company. The policies apply to all employees seconded to the Company and contain specific arrangements that account for tasks and remuneration arrangements in place for the Board, persons running the business, those having Key Functions and those individuals whose professional activities within the Company have a material impact on the risk profile ("Material Risk Takers").

This policy is owned by the Board who acts as the Company's Remuneration Committee. The Board is responsible for the establishment of general principles through the approval of the Remuneration Policy. The Board has the oversight of the implementation of the policy. The Company is required to identify 'the administrative or supervisory body, persons who effectively run the undertaking or have other key function and other categories of staff whose professional activities have a material impact on the undertaking's risk profile', which are collectively referred to as the Solvency II-identified staff and are classified in the following four categories:

- Board Members;
- EXCO Members;
- Management that require MFSA's pre-approval, Significant Influence Functions ("SIF") holders and key function holders; and
- Material Risk Takers.

Further to the above, Material Risk Takers are identified as employees who:

- demonstrate the ability to take material risks;
- demonstrate the ability to influence material risk taking; and
- are responsible for specific activities which have a material impact on the risk profile of the Company, despite not being part of the Company but are part of HSBC Group.

#### **B.1.3.1** Components of Remuneration

The Company's remuneration policy consists of both fixed and variable components, as described below:

(1) Fixed Pay

The purpose of the fixed pay is to attract and retain employees by paying market competitive rates for the role, skills and experience required. These payments are fixed and do not vary with performance. Salary is determined, calculated and paid in line with internal policies and procedures set by the Company, and based on the level of complexity and accountability of the role as described in the corresponding role profile, with the focus on total compensation competitiveness within internal peer group and the external market.

## (2) Variable Pay

The main aim of annual awards is to drive a reward performance and risk based culture within the Company. These are based on annual financial and non-financial measures consistent with the medium to long-term strategy of the HSBC Group, shareholder interests and adherence to HSBC values. A portion of the annual award may be deferred, in the form of HSBC Shares, typically vesting over a period of at least 3 years. The annual variable pay award is discretionary, and is determined and paid in line with internal policies and procedures set by the Company.

### **B.1.3.2** Performance Criteria

Employees' individual performance results and achievements are assessed through the Performance Management process. At the beginning of the performance year, both financial and non-financial goals are set for each employee and formalised through the 'performance scorecard framework'. The progress towards the set goals is the basis for the performance assessment by the employee's manager at the end of the performance year. The assessment is discretionary rather than formulaic. The assessment takes into account behavioural aspects of how the performance goals were reached and uses the 'HSBC Values and Business Principles Behaviour Guide' as a reference.

As a result of this assessment, the employee is assigned a performance rating based on a 4-rating scale. Employees are awarded a separate 'HSBC Values' rating which influences their overall performance rating where appropriate.

# B.1.3.3 Supplementary pension or early retirement schemes for members of the administrative, management or supervisory body

The Company's remuneration policy does not include any supplementary pension or early retirement schemes for Board or other key function holders.

# B.1.4 Material Transactions with Shareholders, with persons who exercise a significant influence on the undertaking, and with members of the administrative, management or supervisory board.

No dividend had been paid in 2021.

There were no other material transactions with Shareholders, with persons who exercise a significant influence on the undertaking, and with members of the administrative, management or supervisory board, other than transactions in the normal course of business.

Related party transactions are presented in Note 27 in the Audited Financial Statements.

# **B.2** Fit and proper requirements

## B.2.1 Description of the fit and proper requirements of the Company

The Company has in place a Fit and Proper Policy, which sets out the principles that are applicable to Directors, Key Function Holders, Critical Function Holders and Outsourcing Monitoring Officers of Key Functions.

The fit and proper assessment is carried out to assess an individual's suitability to perform a key / critical function. It will vary depending on the role that the individual carries out. A report is presented to the Board providing a summary and the outcome of the assessment for the key / critical function holders. In particular, the assessment will consider:

- Time Commitment;
- Knowledge, skills and experience;
- Independence;
- Reputation, honesty and integrity

These criteria also apply to Board members. Two assessments are carried out for Board members – the individual fit and proper assessment and the collective fit and proper assessment. A report is presented to the Board providing a summary and the outcome of the assessment for Board members.

In line with Solvency II requirements the system of governance of the Company should include at a minimum the following key functions: Risk Management, Compliance, Internal Audit and Actuarial Function. An exhaustive list of these Key and Critical Functions are listed below. The Compliance Function is responsible for the oversight of the application of the Fit and Proper requirements and HR function is responsible for the recruitment process for key / critical role within the function.

Solvency II presents the following definition of the terms 'Fit' and 'Proper'.

- Individuals are considered to be 'Fit' if their professional qualifications, knowledge and experience
  are adequate to enable the sound and prudent management of the Company. An assessment of
  whether an individual is 'Fit' shall involve assessing whether the individual's professional
  qualifications, knowledge and experience as a whole is appropriate to his/her role within the
  Company's business.
- Individuals are considered to be 'Proper' if the individuals are of good repute and integrity. An
  assessment of whether an individual is 'Proper' shall include a person's honesty, reputation and
  financial soundness. This will include, checks on criminal convictions, disciplinary offences and
  supervisory/regulatory aspects.

The Compliance Officer should maintain an up-to-date register of the designated fit and proper persons.

Fit a	nd Proper Roles <sup>2</sup>		Should be included in F&P Register	MFSA approval Required	Minimum Experience Requirement
The B	Board				
1	Chairman of the Board & Other Board Members	Simon Vaughan Johnson (Chairman) Muriel Rutland Marisa Attard Joanne Aquilina Phil Blackmore (subject to Regulatory approval) Eric Emoré Charlotte Cilia	Yes	Yes	Insurance experience (or similar role in financial services): not less than 5 years during the
2	Chief Executive Officer (CEO)	Muriel Rutland	Yes	Yes	last 7 years or Insurance
3	Distribution Oversight Director	Muriel Rutland	Yes	Yes	managerial experience (or similar role in
4	Risk Oversight Director	Marisa Attard	Yes	Yes	financial services): not less than 3 years
Key	and Critical Functions				during the last 7 years
3	Head of Risk Function	Chris Plank	Yes	Yes	or In case of non- qualified
4	Head of Actuarial Function	Vikash Shah	Yes	Yes	personnel adequate practical
5	Approved Actuary	This role is currently vacant and the Company is in the process of identifying the new Approved Actuary	Yes	Yes	experience in insurance
6	Head of Insurance Finance	Frank Marqué	Yes	Yes	

 $<sup>^{\</sup>rm 2}$  Fit and Proper Roles as at 28 March 2022.

	T	1			
7	Head of Internal Audit	Morgan Carabott	Yes	Yes	
8	Compliance Officer	Paul Saliba	Yes	Yes	
9	Money Laundering Risk Officer (MLRO)	Paul Saliba	Yes	Yes	
10	Chief Operating Officer (COO)	Anton Gatt	Yes	Yes	
11	Manager, Underwriting & Claims	Edward Micallef	Yes	Yes	
12	Chief Investment Officer	Ritienne Pisani	Yes	Yes	
13	Distribution Oversight Manager	Josef Camilleri	Yes	Yes	
14	Risk Outsourcing Monitoring Officer	Marisa Attard	Yes	Yes	
15	Audit Outsourcing Monitoring Officer	Joanna Aquilina	Yes	Yes	
16	Actuarial Outsourcing Monitoring Officer	This role is currently vacant and the Company is in the process of identifying the new Actuarial Outsourcing Monitoring Officer	Yes	Yes	

 $The \ minimum \ additional \ qualifications \ required \ for \ individuals \ holding \ key \ functions \ are \ detailed \ below:$ 

Key Function	Qualification					
Risk Management Function	Risk Management qualification from a reputable professional or tertiary education institution; or					
	<ul> <li>Financial services qualification from a reputable professional or tertiary education institution; or</li> </ul>					
	<ul> <li>Engineering/Scientific qualification from a reputable professional or tertiary education institution.</li> </ul>					
Compliance function	Legal qualification from a reputable professional or tertiary education institution; or					
	Financial services compliance qualification from a reputable professional or tertiary education institution; or					

Key Function	Qualification
	Other financial services qualification from a reputable professional or tertiary education institution.
Internal Audit function	<ul> <li>Internal/Quality auditing qualification from a reputable professional or tertiary education institution; or</li> </ul>
	<ul> <li>Financial services (including accounting) qualification from a reputable professional or tertiary education institution; or</li> </ul>
	<ul> <li>Scientific qualification from a reputable professional or tertiary education institution.</li> </ul>
Actuarial function, where the insurance undertaking carries	Fellow of the Institute and Faculty of Actuaries (UK); or
on with-profits business and/or life insurance business with guarantees	<ul> <li>Actuarial qualifications of similar standing from a reputable institute.</li> </ul>

The requirement for fit and proper extends to the Board, which in addition to individual assessments, collectively should contain the qualifications, knowledge and experience to be able to provide for the sound and prudent management of the undertaking. The knowledge should be taken both on an individual and collective level, ensuring that the knowledge is diversified and sufficient across the Board.

#### B.2.2.1 Initial fit and proper assessment

As part of the initial fit and proper assessments undertaken at recruitment stage for key / critical or directorship roles, the Company vetting team carry out various checks including: identity checks, criminal record checks, credit checks, verification of employment history and confirmation of educational and professional qualifications. Enhanced fit and proper checks are required for Directors and key / critical function holders, which are also subject to MFSA approval. These include financial checks, external directorship and conflict of interest checks, a civil litigation check, media research checks and regulated position history checks.

## **B.2.2.2** Ongoing fit and proper assessments

Ongoing assessment of the Fitness and Properness of Directors and Key and Critical Function holders and those officers having oversight over Outsourced Key Functions (OMOs) is undertaken on an annual basis. The role of the reviewer is to ensure that Directors and individuals performing Key and Critical Function roles complete the Ongoing Assessment Declaration.

Directors and Key / Critical function holders are required to notify Company Secretary / Compliance Officer in the event of change to their fitness and/or properness. The Compliance Officer shall notify the MFSA of any necessary and relevant changes.

Evidence of Ongoing Assessment Declarations is maintained by Human Resources for Key and Critical Function Holders and the Company Secretary for the INMT Board members.

A report on the outcome of the ongoing fit and proper assessments for both Directors and Key / Critical function holders is presented to the Board on an annual basis.

## **B.2.2.3** Key function holders re-assessments

The fitness and propriety of employee key function holder needs to be re-assessed (i.e. all checks and enhanced checks to be undertaken anew) in line with the Fit and Proper Policy in cases of:

- Promotions;
- Material changes or a change in the scope of the individual's roles and responsibilities where the new or existing role is a key function role; and
- Appointments on the Board.

#### **B.2.2.4** Collective Assessment of the Board

The Chairman of the Board, in conjunction with the Company Secretary, should determine the skills required collectively by the Board, considering qualifications, knowledge and experience and any other aspects considered to be relevant in each of the following areas:

- Insurance and Financial Markets;
- Business Strategy and Business Model;
- System of Governance;
- Financial and Actuarial Analysis; and
- Regulatory Framework and Requirements.
- Risk Management;
- Auditing;
- Cyber Security;
- Standard of Conduct;
- Time Commitment; and
- Independence

The assessment of the Board's fitness should take into account not only the individual assessment for fitness and propriety, but also the assessment of collective skills ensuring that the Board, collectively, has the knowledge of the above areas.

The reassessment of the Board's collective and individual compliance with the Fit and Proper requirements shall be undertaken on an ongoing basis by the Company Secretary, this being at least annually or when a member resigns or retires and when a new member is elected. When re-assessing the individual or collective performance of the members of the management body, the Board considers in particular:

- the efficiency of the management body's working processes, including the efficiency of information flows and reporting lines to the management body taking into account the input from internal control functions and any follow-up or recommendations made by those functions;
- the effective and prudent management of INMT, including whether or not the management body acted in the best interest of INMT;
- the ability of the management body to focus on strategically important matters;
- the adequacy of the number of meetings held, the degree of attendance, the appropriateness of time committed and the intensity of directors' involvement during the meetings;
- any changes to the composition of the management body and any weaknesses with regard to individual and collective fitness and properness, taking into account the INMT's business model and risk strategy and changes thereof;
- any performance objectives set for the institution and the management body;

- the independence of mind of members of the management body, including the requirement that decision making is not dominated by any one individual or small group of individuals and the compliance of members of the management body with the conflict of interest policy;
- the degree to which the composition of the management body has met the objectives set in the INMT's diversity policy; and
- any events that may have a material impact on the individual or collective fitness and properness
  of the members of the management body, including changes to the INMT's business model,
  strategies and organisation.

## B.2.2.5 Fit and proper assessments with respect to outsourced key functions

When any of the Company's key functions is outsourced, the CEO and COO should designate a person with overall responsibility for the outsourced key function that is Fit and Proper and possesses sufficient knowledge and experience regarding the outsourced key function. This person should be able to challenge the performance and results of the service provider. The designated INMT outsourcing monitoring officer (OMO) needs to be assessed for the fitness and proprietary in terms of this policy. If the OMO is designated to oversee the outsourcing of a key function (OMOKF), the enhanced fitness and propriety checks for key function roles apply. In addition, the outsourcing monitoring officer needs to be notified to the MFSA and is considered to be responsible for that key function.

When outsourcing a key function, the OMOKF is to ensure that the fitness and propriety of staff within outsourced entities is undertaken in line with this policy. The INMT OMOKF for the respective outsourced activity is required to obtain written evidence from the outsourced party, that the fitness and propriety of the persons within the outsourced party working on INMT matters has been assessed and the basis on which this has been assessed. Confirmation of the type of check/assessments undertaken also needs to be obtained.

# B.3 Risk management system including the own risk and solvency assessment

## **B.3.1** Risk management system

### B.3.1.1 Description of the risk management system and processes

The Risk Management Function (RMF) governs the overall management of risk exposures to which the Company is or may be exposed to. It encompasses multiple risk types and focuses on optimising the balance and interaction of the different types of risks as well as that between risk and return. The RMF provides an effective and efficient approach to govern and oversee the organisation as well as monitoring and mitigating risks.

The RMF promotes increased risk awareness throughout the Company and facilitates better operational and strategic decision-making, promotes a strong risk culture and ensures that the Company operates in line with the nature and level of risk that stakeholders are willing to take on.

The Board sets the Company's strategy, business plans, performance targets, risk appetite and risk tolerance limits, and in so doing, the Board assumes an essential role in providing the 'tone from the top' to embed the risk culture within the Company.

The day-to-day responsibility of the RMF is facilitated through the risk governance structures in place which support reporting and escalation. Policies, procedures and risk limits are appropriately defined to ensure activities remain within the Company's acceptable level of risk.

The identification, measurement, monitoring and reporting of risks is an essential element of both the day-to-day and strategic decision-making processes. This is supported by effective internal control

processes and regulatory and compliance awareness to ensure that Solvency II requirements are adhered to at all times.

All employees have a role to play in the Company's risk management strategy. Fundamental to the RMF is the implementation and operation of the Three Lines of Defence Model, which takes into account the Company's business and functional structures. The model delineates management accountabilities and responsibilities with respect to risk management and the Company's internal control system, thereby creating a robust control environment to manage inherent and emerging risks.

# B.3.1.2 Integration of the risk management system into the Company's organisational structure and decision-making processes

Active risk management helps us to achieve our strategy, serve our customers and communities, and grow our business safely. Our risk management approach follows five steps:



## B.3.1.3 Definition of Risk Appetite ("Define and Enable")

The Company's business strategy is to support HBMT's strategy in Wealth Management by aligning its propositions, distribution, people and operations to make HSBC the trusted provider of customers' financial future.

The overriding risk management objective is to manage the inherent risks within the Company to create value to the business and to safeguard the interests of both policyholders and key stakeholders.

The risk management strategy is closely aligned with the HSBC Group's strategic objectives and business plans and enables:

- an understanding of the most significant risks faced by the Company;
- the determination and allocation of risk-based capital; and
- effective decision making around business opportunities.

The following are the key elements of the Company's risk management strategy:

- Risk Management objectives demonstrate risk management's support of the Company's strategic objectives;
- Risk Management Principles agreed principles on risk management which guide implementation of the strategy;

- Risk Appetite framework for managing the risk profile in line with the Company's objectives, including approved risk tolerance limits; and
- Risk Governance risk management strategy drives the risk governance structure and roles and responsibilities.

The risk management approach is reviewed annually and aligned with the annual business planning process. In conjunction with this process the Company's FRP and the Risk Appetite Statement ("RAS") are delivered and communicated to all stakeholders, as appropriate. The RAS establishes limits and tolerances for the business and committees to monitor against (supported by Capital Drivers).

#### B.3.1.3.1 Risk appetite

The risk appetite is the Board's articulation of accepted and tolerated levels of risk and return on an enterprise wide perspective. The risk appetite provides the anchor between the strategy, risk and finance, enabling Management to optimally allocate capital to finance strategic growth within tolerated risk levels. It provides a view on the medium to long term horizon, and should be used to monitor performance against the Company's FRP.

The Company's risk appetite is established in line with the risk management strategy and objectives. It is expressed in terms of qualitative and quantitative targets which determine how the business will be managed.

The risk appetite contributes significantly to a strong and integrated risk management framework and risk culture, helping direct and support sustainable growth against the backdrop of a heightened risk environment.

Quantitative aspects of risk appetite, monitored through tolerances and limits, are defined within the RAS. The RAS is approved annually by the Company's Board.

Where a risk assessment identifies that any risk falls outside the boundaries of the Company's risk appetite, now or projected in the future, further steps are taken to control, transfer or mitigate the risk.

## B.3.1.3.2 Risk Identification and Assessment ("Identify and Assess")

The risk identification element in the above map is the process through which the key risks faced by the business are identified, such that they are quantified, controls developed and the risks monitored and managed.

Identified risks are categorised into a risk category or sub-category to aid effective management and mitigation.

Risk identification includes determination of the category of risk and of the circumstances which would give rise to a loss event. The key categories and sub categories are included in the sections that follow.

The risk assessment process quantifies the materiality and magnitude of the risk, considering both likelihood of occurrence and potential impact.

The quantification of risks, which aids effective 1 in a 200-year event risk management by calculating the capital required to be held for each risk type and provides management with quality information to support effective decision-making through, at least, quarterly calculation of the Company's SCR.

Where appropriate, stress tests and scenario analysis are carried out with regard to all relevant risks to ensure risks are effectively understood and quantified.

# B.3.1.3.3 Risk Monitoring ("Manage")

Effective monitoring allows business areas to provide senior management with timely information on the risks facing the Group, and on the effectiveness of risk management processes. It enables proactive identification of issues before they materialise and can provide a forward-looking view of risk. Controls are designed to enable effective risk mitigation and help comply with legal and regulatory obligations. A combination of local and Group policies define the minimum control requirements to ensure appropriate management of each risk type.

## B.3.1.3.4 Risk reporting ("Aggregate and Report")

Risk reporting enables senior management and stakeholders to make informed decisions by providing insightful analysis from accurate and timely data together with subject matter expert perspectives from across the Three Lines of Defence. Reporting requirements will vary by risk type and the severity of risks. Ultimately risk reporting to the board is undertaken through the enterprise wide risk management reports which include the Risk Appetite Profile, the Risk Map and a summary of the Top and Emerging Risks.

#### B.3.1.3.5 Governance ("Govern")

Board governance committees, including the meeting of the Board of Directors and the Audit and Risk Committee, provide the structure to ensure clear accountability for risks and support suitable controls, mitigation and management.

## **B.3.2** Own risk and solvency assessment

#### **B.3.2.1 ORSA Process**

The overall aim of the ORSA is to demonstrate the adequacy of the Company's capital base, taking into consideration the Company's Capital Management Framework which drives dividend recommendations, and the Company's resilience to a wide range of outcomes. In particular, it aims to:

- (a) Assess the Company's overall solvency needs, taking into account all risks that affect the Company, approved risk tolerance limits and business strategy, both during the calendar year and over the business planning period;
- (b) Test the appropriateness of the Capital Management Framework over the business planning period against the results of stress and scenario testing performed;
- (c) Demonstrate compliance, on a continuous basis, with the capital requirements and requirements relating to technical provisions;
- (d) Analyse the extent to which the risk profile deviates from the assumptions underlying the capital requirements;
- (e) Identify areas of Company or customer risk, or matters relating to solvency calculations or model structure, that require further analysis or action and to recommend the next steps in relation to those areas;
- (f) Demonstrate the adequacy of management actions and recovery plans; and
- (g) Provide evidence that the assessment of risk and solvency is an integral part of the business strategy and is taken into account on an on-going basis in strategic decisions.

The ORSA Process is ongoing and continuous with management reports such as the Risk Appetite Profile being undertaken monthly, valuations being reported quarterly and risk and control assessments happening on an ongoing basis.

The results of the ORSA processes form part of the Company's business strategy and are taken into account, on an on-going basis, in the strategic decisions of the Company. In particular, the Company's ORSA results are taken into account in its medium term capital management, business planning and

product development and design. The results of the economic capital calculations produced by the SCR model which are a part of the overall ORSA process are used as part of key business decision making processes, the system of governance and the risk management system as outlined below:

- Risk reporting Economic capital data from the model is a developing component of risk management information to the various Risk and Management Committees;
- Setting of the overall risk appetite The model is extensively used in the setting of the Company's overall risk appetite (including the setting of underlying risk limits and risk metrics);
- Risk management system The role and use of the model in relation to the risk management system, includes the establishment of the Company's risk appetite (including the underlying risk limits and risk metrics), quantification of risks, capital assessment, capital allocation, stress testing and scenario analysis;
- Product development and pricing The model is used to determine key profitability and capital
  metrics, and facilitates the ongoing monitoring of the profitability of major product lines. The
  outcome of the monitoring process is subsequently taken into account during future price reviews;
  and
- Reinsurance retention and pricing The model is used to determine the optimum reinsurance level
  and provides basis to negotiate the reinsurance premium to be paid to the reinsurer upon renewal
  of the contract.

## **B.3.2.2 ORSA Roles and Responsibilities**

- The Board is responsible for how the ORSA assessment is performed and for challenging its results, together with approving the ORSA Report and approving the ORSA Policy on an annual basis.
- The RMF, as the Second Line of Defence, is responsible for coordinating the execution of the ORSA process, including the drafting of the ORSA Report, reviewing the ORSA Policy and ensuring that the results and conclusions are communicated to all relevant employees. It is also responsible for ensuring that the ORSA process undergoes regular review which would typically be undertaken by Internal Audit (the last review was completed in 2018). During H2 2021, a HSBC Independent Model Review (IMR) has been concluded for the Regulatory Capital and Economic Capital Models.
- The Actuarial Function is responsible for assessing compliance with the requirements regarding the technical provisions and the risks arising from the capital requirements calculations.
- The Actuarial Function is also responsible for providing the necessary calculations to the RMF and
  for providing input into the actuarial aspects of the report. The aforementioned calculations include
  the actuarial calculations in relation to regulatory capital, economic capital, forward-looking
  assessments and analysis, as well as stress and scenario analysis.
- The Finance Function is responsible for performing the non-actuarial calculations such as business planning and liquidity planning, and for providing input into the Finance aspects of the report.

# **B.3.2.3 ORSA Reporting**

The ORSA Report is prepared on a regular basis, at least annually, and without delay following any significant change in the Company's risk profile or external environment by the Head of Risk Function. The ORSA Report is subsequently presented to Management for consideration and the Board for its approval. The report covers the period since the previous ORSA assessment.

To support the creation of the ORSA Report there are a series of supporting documents and reports which are presented to Management and, where appropriate, the Board. These include:

- The Risk Appetite Statement and monthly reporting against this in the Risk Appetite Profile;
- Risk Map and Top Risks of the Company;
- Summary of the Emerging Risks of the Company;
- The quarterly Solvency Capital Valuation Reports which assess the Company's capital position;
- Updates on previous ORSA recommendations.
- The policies, such and the ORSA Policy, Risk Management Framework and Capital Management Framework, which set the frameworks which the Company must operate within; and
- More detailed reports on specific ORSA deliverables such as scenario testing and the Standard Formula justification.

Results of the ORSA activities are presented to relevant employees, Management and the Board through the governance meetings of the Company and through a dedicated walkthrough session held by the Head of the Risk Function.

## B.3.2.4 Own solvency needs and the interaction between capital and risk management

The capital requirement calculations are based on the Standard Formula (including the correlations between risk types). The appropriateness of the Standard Formula vis-a-vis the Company's risk profile is assessed on an annual basis. Through this process the Company consider whether the risk is material, whether the standard formula is a good fit and whether there is sufficient data to calibrate and 'Internal Model'. The process which is undertaken as a part of the ORSA demonstrates that the use of the Standard Formula is appropriate.

Notwithstanding this, the Company holds a capital buffer in line with its Capital Management Framework, while also taking into account the Company's Risk Appetite, scenario analysis results, historic volatility and market practice. The Capital Management Framework is directly linked to the RAS and is monitored through the risk management information. The RAS also sets out an appetite for the capital held against each risk category.

## **B.4 Internal control system**

#### **B.4.1 Description of the internal control system**

The Company maintains an adequate internal control framework commensurate with the scale and nature of its operations. A proper internal control environment is of fundamental importance and is a process effected by all levels of staff, at all times. The business operates in an efficient manner with proper controls in place to safeguard assets, operations and records in order to manage operational risk within the Company's risk appetite and to preserve the integrity of financial reporting.

Key controls of the Company are documented across the Risk Management Policy and the HSBC Group risk and control taxonomy. Under the HSBC Group framework, the risk and control processes for operational risks include the following:

- Undertaking an inherent risk assessment which assesses the maximum plausible impact on the business over the next 12 months assuming day to day management controls are in place but before considering controls specifically mitigating risk events for a specific risk instance.
- Where risks have been inherently risk rated as Very High or High or the business has determined Locally Significant Risks from the Inherently Medium and Low Risks, a full Risk and Control

Assessment (RCA) is carried out. All controls are assessed in order to determine the control effectiveness by the control owner.

- All controls identified in the RCA are compiled into an Internal Control Monitoring Plan and an
  Internal Continuous Monitoring Plan (ICMP) where depending on the severity of the risk, the
  effectiveness of the control is tested or continuously monitored on a quarterly, half yearly or annual
  basis. Control Testing and Continuous Monitoring results are shared in the Risk and Control Forum
  and outcomes/results are reported to the Risk Management Meeting.
- A residual risk assessment is carried out to assess the level of risk remaining in the context of the
  control environment. When a risk has been rated as Very High or High the Risk Owner could take
  action to mitigate the risk through strengthening the processes and/or supporting controls.
  Alternatively, Risk Acceptance can be considered.

In addition, the System of Governance as described in Section B.1.1 is a fundamental component of the internal control system of the Company.

Internal controls are subject to regular monitoring and include the following:

- personnel clear and concise operational procedures available to all personnel to ensure that they
  can understand and carry out their responsibilities effectively and communicate any problems in
  respect of non-compliance;
- organisational structure responsibilities and reporting lines are clearly defined and allocated;
- effective communication lines internally that escalate information quickly to the appropriate level;
- segregation of duties and potential conflicts of interest key duties are segregated; areas of potential conflict are identified and mitigated appropriately;
- authorisation and approval all transactions require authorisation and approval by an appropriate responsible person;
- an established financial control environment includes routine controls such as reconciliations, audit trails, spot checks and physical control with appropriate supervision by management;
- financial reporting is prepared in accordance with Group standards; risk assessments cover all risks facing the entity and are reported regularly;
- reliable information systems are in place to report all significant activities supported by adequate security and contingency arrangements; and
- business resumption and contingency plans are periodically tested to avoid disruption to business and potential losses. Key controls to manage and mitigate specific risk areas are outlined in section C.

# **B.4.2** Implementation on the Compliance Policy by the compliance function

The local compliance function is comprised of Regulatory Compliance ('RC') and Financial Crime Compliance ('FCC').

The Compliance function's scope is focused on discharging their roles as Risk Stewards in relation to RC and FCC risks. The Compliance function discharge this role by setting policies and limits in accordance with determined risk appetites in the RC and FCC areas, as well as providing advice, guidance and challenge relating to these risk activities.

The Compliance function also undertake assurance, monitoring and testing activities to provide assurance that relevant policies are adopted and embedded within the first line and on the appropriateness of key RC and FCC risk management processes.

Compliance activities do not generally focus on areas where other functions are the relevant Risk Steward. However, the Compliance function may be called upon to assist other functions (for example working with HR on regulatory elements of an employee code of conduct, providing advice on remedial action and reporting where a regulatory breach has arisen and supporting activities where other functions identify Compliance Risk (whether RC or FCC risk) as being a secondary risk.

Each of these areas is complemented by the Assurance team. Compliance report on any regulatory and financial crime matters regularly to the Company's RMM and to the Board in respect of their advisory and monitoring activities.

#### **B.5 Internal audit function**

## **B.5.1** Implementation of the internal audit function

The Company outsources the provision of Internal Audit services to its parent company, HBMT, under an Intra-Group Service Agreement. Under this agreement, the Company uses the services of the HBMT's Internal Audit team to deliver the agreed Internal Audit Function services, which meet both Solvency II and Group requirements, and are also in line with best practice. The Internal Audit services are delivered in accordance with a multi-year Internal Audit Plan approved by the Audit and Risk Committee covering all key functional areas and providing an evaluation of the adequacy and effectiveness of the internal control system and other elements of the system of governance. A four-year Internal Audit cycle is generally presented to the Audit and Risk Committee for approval.

## B.5.2 Independence and objectivity of the internal audit function

The Internal Audit Function, as the Third Line of Defence, is independent of the First and Second Lines of Defence. The function reports to the Audit and Risk Committee, which is also responsible for the oversight of the outsourced Internal Audit Function.

The persons carrying out the internal Audit Function do not assume any other Key Functions within the Company.

#### **B.6 Actuarial function**

#### **B.6.1** Implementation of the actuarial function

The Actuarial Function is outsourced to the HSBC Group and headed by the approved Chief Actuary who reports to the Regional Chief Actuary.

The Chief Actuary currently has a direct reporting line to the Board and is responsible for:

- Co-ordinating the calculation of the technical provisions;
- Ensuring the appropriateness of the methodologies and underlying models used, as well as the assumptions made in the calculation of technical provisions;
- Assessing the sufficiency and quality of data used in the calculation of technical provisions;
- Comparing the best estimate against experience;
- Informing the governing body of the reliability and adequacy of the calculation of technical provisions;
- Expressing an opinion on the overall underwriting policy;
- Expressing an opinion on the adequacy of reinsurance arrangements;
- Contributing to the effective implementation of the risk management system, with particular regard to risk modelling by the firm.

The Actuarial Function contributes to the effective implementation of the risk management system through various activities and the membership of a number of key committees with risk and financial reporting responsibilities. Areas of focus include: Solvency Capital Requirement; the Own Risk and Solvency Assessment; identifying, measuring and monitoring risks; capital adequacy management; product pricing; financial reporting; and business planning.

The Chief Actuary also has oversight duties in relation to key risk management, risk mitigation techniques, data accuracy, claims management, and underwriting and reinsurance agreements in place.

The Chief Actuary is a Fellow of the Institute and Faculty of Actuaries and continues to comply with the specific professional obligations this requires. The Chief Actuary is supported by Fellows and student members of the Institute and Faculty of Actuaries.

The Company's Head of the Risk Function and subsequently a non-executive Director were designated as the person responsible for the oversight of the outsourced Actuarial Function until 30 August 2021 and 16 February 2022 respectively. This role is currently vacant and the Company is in the process of identifying the new Actuarial Outsourcing Monitoring Officer.

#### **B.7 Outsourcing**

The Outsourcing standards applied by the Company set out a structured approach to the establishment and management of arrangements with service providers. They have been established to ensure the risk from outsourcing does not impair the Company's financial performance or the soundness of the activities and quality of services to customers.

Service providers are required to meet HSBC Group standards. These include, but are not limited to, the following areas:

- Secure handling of HSBC and customer information;
- Standards of customer care:
- Continuity of service; and
- Compliance with all applicable laws and regulations.

The Company classifies the outsourcing agreements currently held as follows:

- 1. "Outsourcing" or "non-Outsourcing"
- 2. If outsourcing, then further classified as "Critical/Important" (including Solvency II defined Key Functions) or "Non-Critical/ Non-important"

Agreements falling under Critical or Important functions or activities include:

- a) the design and pricing of insurance products;
- b) the investment of assets or portfolio management;
- c) claims handling;
- d) the provision of regular or constant compliance, internal audit, accounting, risk management or actuarial support;
- e) the provision of data storage;
- f) the provision of on-going, day-to-day systems maintenance or support;
- g) the ORSA process.

The following activities are not considered critical or important operational functions or activities:

a) the provision of advisory services to the undertaking and other services, which do not form part of the undertaking's insurance or reinsurance activities, such as legal advice, the training of personnel and the security of premises and personnel;

- b) the purchase of standardised services, including market information services and the provision of price feeds;
- c) the provision of logistical support, such as cleaning or catering;
- d) the provision of elements of human resources support, such as recruiting temporary employees and processing the payroll.

The Company remains fully responsible when outsourcing any of its functions or activities. The main rationale for outsourcing is to obtain the necessary expertise and resourcing required by the Company.

The Company appoints Third Party Engagement Managers ("TPEMs") for every outsourcing agreement entered into. The Outsourcing Policy is applicable to all TPEMs including employees responsible for the oversight and monitoring of Critical/Material or Important operational functions or activities.

The following table presents detail on the Company's outsourcing of Critical/Material or Important operational functions or activities:

Third Party	Activity	Third Party Engagement Manager (TPEM) Job Title	Jurisdiction of Service Provider	Type of Agreement
HSBC Group Management Services Ltd	Actuarial Function	Position Vacant	United Kingdom	Key Function
HSBC Group Management Services Ltd	Head of Risk Function	Independent Non-Executive Director	United Kingdom	Key Function
HSBC Bank (Malta) P.l.c	Internal Audit	Independent Non-Executive Director	Malta	Key Function
RGA International Reinsurance Company Limited	Reinsurance incl. Claims Handling	Products & Distribution Senior Manager	Ireland	Critical or Important Activity
HSBC Electronic Data Processing Lanka (Private) Ltd	Tax Reporting (CRS) Support	Head of Insurance Operations & Business Standards	Sri Lanka	Critical or Important Activity
HSBC Electronic Data Processing Lanka (Private) Ltd	Tax Reporting (FATCA) Support	Head of Insurance Operations & Business Standards	Sri Lanka	Critical or Important Activity
HSBC Global Asset Management (UK) Ltd	Investment of Assets - Portfolio Management	Chief Investment Officer	United Kingdom	Critical or Important Activity
Schroeder Investment	Investment of Assets -	Chief Investment Officer	Luxembourg	Critical or Important Activity

Management	Portfolio			
(Europe) SA	Management			
HSBC Global Asset	Investment of	Chief Investment	Malta	Critical or
Management (Malta)	Assets -	Officer		Important Activity
Ltd	Portfolio			
	Management			
HSBC Electronic Data	Financial	Head of	India	Critical or
Processing India	Accounting	Insurance		Important Activity
(Private) Ltd		Finance		

In addition, the Company has the following Intra-Group outsourcing arrangements:

Service Provider	Description of service outsourced	
Internal (HSBC Group)		
1. HSBC Bank Malta p.l.c.	The Company outsources management services to HSBC Bank Malta p.l.c, which include human resources, property services, IT and Legal.	
2. Other HSBC Group Companies	Other Group companies provide investment accounting and unit pricing services to the Company.	

# B.8 Adequacy assessment of the system of governance

Effectiveness reviews of the Board, the Committees and Forums are completed on an annual basis by the Board/Committee/Forum Secretary. The Board is presented with a 'Corporate Governance Framework' once a year for review and approval. The document contains the latest organisation and governance charts; the Board, Committee and Forum Terms of Reference; the Governance and Reporting Calendar; and the Internal Audit Plan. Furthermore, the Company undertakes a formal review of the system of governance which includes as assessment that mapping to regulations, policies, Committees' Terms of Reference and effectiveness reviews have been updated. In addition, any open issues and findings are also reported.

On an annual basis the CEO leads a review of the System of Governance which is presented to the Board for approval. Where any issues are identified management actions plans are created to address findings.

# **B.9** Any other information

There is no other material information regarding the system of governance that has not already been disclosed in sections B.1 to B.8 above.

## C. Risk profile

#### **C.0** Risk Exposures

Risks are assessed quantitatively using the Standard Formula parameters to determine the impact of an extreme event for each risk and thus internal data is not used to define the parameters or the dependencies and correlations between risks. As described in B.3.2.4, the standard formula is considered an appropriate measure of the risk exposure for the key risks such as underwriting, market, credit and operational risk (as set out in C.1, C.2, C.3 and C.5). The table below sets out the Company's exposure to these risks:

Solvency Capital Requirement (without diversification benefit)	2021	2020
	€′000	€′000
Underwriting Risk	30,850	31,846
Market Risk	17,106	18,240
Credit Risk	6,997	1,221
Operational Risk	1,492	1,494

The Company's highest risk exposure is within the underwriting risk module and arises from mass lapse. The primary driver for this is a reduction in own funds on contracts where the best estimate liabilities are negative, meaning that the policy is expected to generate a profit over its remaining term, and thus in the event of a mass lapse event the Company will lose out on future profits. The Company's second highest risk is within the market risk module, with equity risk being the largest component. Equity risk arises from the reduction in annual management income on Unit-Linked business and the increase in the cost of guarantees on the With-Profits business under the equity stress.

A description of the risks, the exposure to the risks, control and mitigation techniques and concentrations to particular risk sub-categories are set out below.

Market risk has reduced from previous year due to a reduction in the capital required to support the financial guarantees underlying the With-Profits book under stress following an increase in the fund surplus. This is offset by the increase in market risk capital following the allowance for the shareholder profits from the distribution of the fund surplus.

The Credit risk capital has increased over the year, mainly driven by the revision of the credit rating categorisation for counter-parties with which cash is held, which has changed to 'unrated' at year-end 2021, to reflect their categorisation as unrated Credit Institution resulting in an increase in type 1 counterparty exposure.

Apart from that, there are no material changes in the Company's significant risk exposures or in the measures used to assess such risk exposures over the reporting period.

# **C.1 Underwriting Risk**

This is the risk due to uncertainties in the occurrence, amount and timing of insurance liabilities arising through insurance underwriting risks accepted by the Company. In more detail it includes:

• The risk due to uncertainties in the occurrence, amount and timing of claim payments. This includes mortality (or longevity), disability and catastrophe risks. Experience could differ from expectations

- because of random fluctuations, an unanticipated one-off step change, a gradual change or a catastrophe or pandemic meaning claim sizes and volumes are above expectations.
- The risk due to uncertainties in the occurrence, amount and timing of lapses, surrenders or making
  policies paid-up. Experience could differ from expectations because of random fluctuations, an
  unanticipated one-off step change or a gradual change or a lapse shock resulting in lapse of a large
  number of policies over a short time period.
- The risk due to uncertainties in the occurrence, amount and timing of expenses. Experience could differ from expectations because of random fluctuations, an unanticipated one-off step change or unanticipated changes in inflation.

Exposure to these risks is as follows:

Solvency Capital Requirement (without diversification benefit)	2021	2020
	€′000	€′000
Mortality Risk	468	611
Longevity Risk	194	209
Disability Risk	1,516	1,568
Lapse Risk	26,144	27,176
Expense Risk	6,722	6,644
Catastrophe Risk	1,553	1,613
Diversification Benefit	(5,727)	(5,976)

The Company have a wide variety of controls in place to manage and mitigate the underwriting risks which are faced. Reinsurance is the primary mitigation for claims risk where in effect, claims risk is exchanged for counterparty risk. Upon the placement of reinsurance an optimisation process is undertaken. Other controls include the following:

- Exposure limits are set which are based on a variety of factors. Limits are set in respect of absolute exposures (for example maximum policy sizes) and in relation to the overall capital that the company which to deploy (e.g. monetary or percentage capital limits against a specific risk types).
- Capital and solvency monitoring through regular valuations and the Risk Appetite Profile.
- Clear underwriting and claims management principles are set. This includes the setting of underwriting and claims authority levels.
- Monitoring of actual experience versus what is expected. Where experience in not in line with
  expectations the underlying valuation assumptions can be changed and where required this may
  trigger product changes, such as the repricing of new business.
- Having robust product design and approval processes (including appropriate policy conditions to guard against unacceptable risk).

#### **C.2 Market Risk**

This is the risk of adverse movements in market rates that change the value of assets net of liabilities causing losses to the Company. This can impact the Company, but not limited to, in the following ways:

• Movements in market rates (including asset prices, equity volatility, interest rates, foreign exchange rates and credit spreads) change the present value of assets net of liability values.

- Changes in value of net assets due to a move in the yield on an asset relative to the risk-free rate.
- Depreciation of foreign currencies relative to Euro changes the present value of assets net of liabilities.
- Fall in value of properties changes the present value of assets net of liabilities.
- Large proportion of assets held in any one risk category or security, resulting in market risk exposure
  to a loss potentially large enough to threaten the solvency or the financial position of the
  undertaking.

Exposure to these risks is as follows:

Solvency Capital Requirement (without diversification benefit)	2021	2020
	€′000	€′000
Interest Rate Risk	2,429	1,384
Equity Risk	8,977	12,582
Property Risk	40	40
Spread Risk	4,478	3,678
Currency Risk	5,350	4,400
Concentration Risk	4,590	2,795
Diversification Benefit	(8,758)	(6,639)

The Company have a wide variety of controls in place to manage and mitigate market risks which are faced. This includes the following:

- Exposure limits are set which are based on a variety of factors. Limits are set in respect of absolute
  exposures (e.g. maximum exposures to particular classes of assets) and in relation to the overall
  capital that the company deploys (e.g. monetary or percentage capital limits against a specific risk
  types).
- Capital and solvency monitoring through regular valuations and the Risk Appetite Profile.
- Setting an overall investment strategy for the Company.
- Asset Liability Matching looks to assess the suitability of assets in meeting the liabilities of the Company.
- Having robust oversight of investment related activities through the governance committees of the Company.

## C.2.1 Investment of assets in accordance with the 'prudent person principle'

The Company fulfils its obligations of the 'Prudent Person Principle' by way of the policies and practices described below. Kindly refer to the submitted QRT templates S.06.02.01 for the complete list of assets.

## **C.2.2 Asset Liability Matching Principles**

# C.2.2.1 Matching: Shareholder

The Company's approach is to select assets to match net cash flows by duration, nature, currency and liquidity. Asset and liability matching ("ALM") mitigates interest rate and liquidity risk exposure. ALM exercises are carried out to:

- assess the suitability of the term and nature of assets held to meet the liability cash flows as they fall due in best estimate and stress conditions;
- identify gaps and any unsuitable assets;
- recommend movements between asset pools to achieve a more appropriate asset allocation (if necessary); and
- identify suitable assets to invest in so as to remove exposure to future unmatched cash flows, hence reducing the volatility of the Company's statutory solvency position and reducing exposure to market risk.

An ALM exercise is performed on a quarterly basis and includes stress testing to assess the suitability of the assets in meeting cash outflows as they fall due.

The quarterly ALM exercise is carried out by the Actuarial Function and subject to the oversight of ALCO.

## C.2.2.2 Matching: Unit-linked

The matching strategy for unit-linked funds is to match the unit-linked technical provisions as closely as possible with asset holdings of units in the appropriate underlying funds.

# C.2.2.3 Matching: With profits

These funds are held to meet a defined liability in respect of underlying insurance policies and the assets held are managed with a view to maximise profits while matching policyholders' liabilities with regards to term and currency and that the guaranteed capital value is not unduly put at risk.

## **C.2.3 Investment Strategy (Shareholder Funds)**

For the assets backing the technical provisions and own funds, the Company's investment strategy is to maximise return subject to adhering to the Company's risk appetite and the prudent person principle. The key elements of the investment strategy are to:

- set the strategic asset allocation;
- consideration of investment constraints when setting strategic asset allocation;
- alignment of the investment strategy with the business model and, where appropriate, how the strategy takes into account the nature and duration of a firm's liabilities and obligations, and the best interests of policyholders;
- alignment of investment strategy with board risk appetite, risk tolerance limits and investment risk and return objectives;

### **C.3 Credit Risk**

This is the risk that a counterparty of the Company will be unable or unwilling to meet a commitment that it has entered into with the Company.

The credit risks arising from fixed income assets are covered in section C.2 Market risk under Spread Risk and Concentration Risk.

Also, the Company has counterparty risk exposures where Cash at bank is the most material, where this exposure is also accounted for within the capital requirement with respect to counterparty default risk.

The Company has also credit exposure to a single reinsurer where this exposure is accounted for within the capital requirement with respect to counterparty default risk. Scenario analysis on the default of this reinsurer is performed to understand the effect of the materialisation of this risk. Credit support clauses are included as part of the reinsurance contract, which protects the Company in the event of a downgrade in the reinsurer's credit rating. The reinsurance currently forms a liability and thus there is no loss given default.

Exposure to these Counterparty Risks is as follows:

Solvency Capital Requirement (without diversification benefit)	2021	2020
	€′000	€′000
Type 1	6,945	1,175
Type 2	69	60

The Company has the following two specific Counterparty Risk exposures:

- (a) Credit exposure to a single reinsurer: this exposure is accounted for within the capital requirement with respect to counterparty default risk. Scenario analysis on the default of this reinsurer is performed to understand the effect of the materialisation of this risk. Credit support clauses are included as part of the reinsurance contract, which protects the Company in the event of a downgrade in the reinsurer's credit rating. The reinsurance currently forms a liability and thus there is no loss given default.
- (b) Cash at bank: this exposure is also accounted for within the capital requirement with respect to counterparty default risk.

The Company have a wide variety of controls in place to manage and mitigate credit risks which are faced. This includes the following:

- Exposure limits are set which are based on a variety of factors. Limits are set in respect of absolute exposures (e.g. maximum exposures to particular investment quality of assets) and in relation to the overall capital that the company which to deploy (e.g. monetary or percentage capital limits against a specific risk types).
- Capital and solvency monitoring through regular valuations and the Risk Appetite Profile.
- Setting an overall investment strategy for the Company.
- Having robust oversight of investment related activities through the governance committees of the Company.

The Credit Risk Capital has increased over the year, mainly driven by the revision of the credit rating categorisation for counter-parties with which cash is held, which has changed to 'unrated' at year-end 2021, to reflect their categorisation as unrated Credit Institution resulting in an increase in type 1 counterparty exposure.

## C.4 Liquidity risk

The risk that the Company, although solvent, either does not have sufficient financial resources to enable it to meet its obligations as they fall due, or can secure them only at excessive cost. Examples of how this could arise are:

- A one-off severe manifestation of the measure of the underlying risk process. For example, a sudden unexpected increase in claims or early surrender of policies results in an inability to pay customers in a timely manner without incurring excessive costs.
- Insufficient liquid assets to cover severe operational losses.
- Lack of suitable assets in the market results in an inability or decision not to match liabilities.
- Assets become unsaleable at fair values when market conditions deteriorate.

The Company holds sufficient liquid assets such that no capital is required and the risk is considered low. This is tested on a regular basis through a series of liquidity scenario testing with additional controls including:

- A liquidity risk dashboard which is tracked regularly through governance committees of the Company.
- Liquidity contingency plans are maintained and trigger events are monitored.
- Asset Liability Matching looks to assess the suitability of assets in meeting the liabilities of the Company.
- Liquidity risk clauses within the Unit Linked Product Terms and Conditions.

## C.4.1 Expected profit included in future premiums

The total amount of the expected profit included in future premiums is €21,690k as at 31 December 2021 (31 December 2020: €28,828k). The fall in the protection profits are mainly due to an unfavourable impact from changes to the lapse assumptions and the positive cash flows that have emerged on the inforce book. These have contributed to a reduction in expected future profit.

#### **C.5 Operational Risk**

This is the risk of loss resulting from inadequate or failed internal processes, people and systems or from external events, including legal risk. During 2021 the Company classified Operational Risks across the following main categories: Financial Reporting; Tax; Resilience; Financial Crime and Fraud Risk (internal and external); People; Regulatory Compliance; Legal and Model.

Each specific risk type will also have a specific set of controls to mitigate and manage it. Where a particular type of Operational Risk has been assessed as material each relevant control should be assessed and the overall control effectiveness for the risk is determined. Controls would be tested and where required actions plans would be put in place to improve their operation.

## C.6 Other material risks

Within the Company's Risk Management Policy, a series of wider risks are also recognised. These include:

- Strategic Risk
- New Business Risk
- Group Risk
- Conduct and Reputational Risk

The Company does not specifically hold capital against these risks but they are tested through the ORSA process and where appropriate specific scenarios are run in respect of the risks.

## C.6.1 Strategic Risk

This is the risk to business plans and strategic objectives resulting from poor execution, inability to adapt to changes in external environment, or failure to meet stakeholder expectations. This could arise through:

- A decision by its parent company (and primary distributor) to cease writing business in the Company, thereby effectively closing to any new business.
- The business agrees a business plan that generates unsustainable financial, operational or customer conduct outcomes. This could involve new business volumes or persistency levels that do not produce the margins required to support an effective and compliant customer service.
- The making of business decisions or resource allocations that are sub-optimal or counter to the stated objectives of INMT and/or the Group.
- The risk that the business will fail to identify and react appropriately to opportunities and/or threats arising from changes in the market.

Controls to manage and mitigate this risk include:

- The FRP process is undertaken which sets out strategic plans for the business which is approved at Board and Group level.
- Tracking against FRP to ensure that actual performance is in line with expectations.
- Consideration of the financial outcomes of different strategic scenarios.
- A robust product approvals process ensures that risks are duly considered and priced for appropriately.

#### **C.6.2 New Business Risk**

The risk of the new business being written being different to that expected with the plans. This could arise through:

- Insufficient volume of policy sales in order to cover costs leading to a strain on capital resources.
- A different mix of business is sold compared to the mix that was expected, which could result in the Company exhausting its free assets over time.
- Selling more policies than expected leading to a strain on capital resources.

Controls to manage and mitigate this risk are that new Business performance is measured weekly against the targets which core capital and operational planning is based. Stress and scenario testing is used as a method of testing the impact of variances and actions agreed in the event of over or under performance, be that in total or in product segments.

## C.6.3 Group Risk

The risk to the Company from operating as an entity within a wider Group. This could arise through:

- Circumstances in which the intended arm's length nature of the Group relationship could be compromised or not operate as expected under stressed circumstances.
- A disproportionate rise in overheads which create either an immediate or prospective adverse capital impact reducing own funds.
- The Group impose decisions or requirements on the Company that are not in its best interests.

Controls to manage and mitigate this risk include:

• All transactions between the Company and the rest of the Group are treated as arm's length arrangements.

- The Company has its own Board of Directors (including Independent Non-Executives) who are ultimately responsible for decision making within the business.
- The Company are required to follow Group policies and practices. However, if these are not appropriate for the business given the nature, scale and complexity formal dispensations can be sought.
- There are agreements in place for all services which are provided by the Group to the Company. These are reviewed on a regular basis.

## **C.6.4 Conduct and Reputational Risk**

The risk that poor conduct with respect to customers leads to compensation and/or fines from the regulator along with reputational damage. This includes areas where the Company can apply discretion (e.g. the setting of bonus rates), in the design of products which are offered to customers, or where the Company has obligations to fulfil for customers. It can arise through:

- Mis-selling, which although is not a risk to the Company, or post sales misconduct occurs has a knock on impact on the reputation of the Company.
- Post sales policy management, notably in areas where the customer has discretion (e.g. the setting of bonus rates).
- Regulators publicise adverse findings which damage HSBC reputation.
- Media or social media publicise adverse findings which damage HSBC reputation and/or industry reputation.

Controls to manage and mitigate this risk include:

- Conduct Risk Dashboard is produced on a periodic basis for business and risk forums to inform management of the key risks and actions being taken.
- Monitoring and assessment of sales quality checks.
- Literature being clear, transparent and meeting regulatory requirements.
- Adherence to the Product Approval Processes.
- Products are operated in line with the Policy Terms and Conditions and other communications.
- Insurance Product Reviews (IPRs) are done to validate that products remains relevant and continues to deliver fair customer outcomes.
- Investment performance is tracked against benchmarks.
- Where discretion can be applied, for example the application of bonuses to with-profit customers, this must be applied in line with the expectations of customers which have been gained through pre and/or post-sale literature or past practices; and any approved policies which are in place within the Company.

## C.7 Stress testing and sensitivity analysis

The business undertakes a wide variety of stress and scenario testing on the Company's Economic Capital position to consider the breadth of risks covered in C.1 to C.6. While certain stress tests can be attributed to a specific risk type there are often occurrences where stresses or scenarios are applicable across a variety of risk types.

During 2021, the Company has conducted a series of scenario tests which are summarised below and are based on discussions which take place during internal scenario workshops. These scenarios were performed using an adjusted 30 June 2021 position as the base, considering the solvency over the planning horizon.

Under all scenarios the Company results in a lower level of solvency over the projected period, some of which would mean that the business is insolvent on a regulatory basis. The drivers for the movements differ based on the scenario circumstances. While the scenarios are extreme and are unlikely to play out in reality, the information should be used to make the management aware of the types of events that would impact the Company materially. The Company would be required to take necessary actions, for example to raise capital.

## C.7.1 Covid 19 Market Volatility

This scenario considers the capital implications as a result of market impacts emanating from the pandemic Covid 19 as well as increased claims. It takes into consideration reduction in equity prices, widening of credit spreads and lower interest rates and mortality spike.

The Company will be insolvent and would be required to raise capital, as it would breach the Solvency Capital Requirement in 2022, i.e. its Available Capital is less than its Capital Requirements. The Company will need to raise Tier 1 capital and could also choose to raise sub-ordinated debt which is a Tier 2 Capital in order to achieve regulatory solvency. The Company currently does not have any Tier 2 and 3 Capital, and therefore, the subordinated debt could be raised to increase solvency up to 50% which is the maximum Tier 2 and 3 Capital eligible for regulatory solvency purposes

### C.7.2 Covid 19 Insurance Underwriting Risk Impact

This builds on the above scenario with taking into consideration additional impacts on the change within policyholder behaviour in terms of changes to lapse behaviour and reduced new business.

As per the comments made in C.7.1, the company would be required to raise additional capital, including Tier 1 capital through e.g. shares in order to achieve regulatory solvency and may consider issuing subordinated debt to achieve a solvent position. The Company would require to present a plan to the MFSA to restore solvency within 3 months.

## C.7.3 Covid 19 Slower recovery of New business volumes

This scenario builds on the Covid 19 Market Volatility and Insurance Underwriting risk scenario, by considering a slower recovery of the New business volumes.

As per the comments made in C.7.1 and C.7.2, the company would be required to raise additional capital, including Tier 1 capital through e.g. shares in order to achieve regulatory solvency and may consider issuing subordinated debt to achieve a solvent position. The Company would require to present a plan to the MFSA to restore solvency within 3 months.

## C.7.4 New business - Property Market Slowdown

Due to the Greylisting of Malta, there may be a decline in mortgage sales and therefore a lower takeup rate on the Loan Protector policies. The scenario analyses the impact on the Company's Projected Balance Sheet as a result of changes in New business volumes. Two scenarios are considered a fall in the Loan Protector new business of 25% and 50%.

The solvency ratio remains above 100% throughout the business planning period under this scenario.

## C.7.5 Local Market Scenario

The scenario analyses the impact on the Company's Projected Balance Sheet as a result of a rise in inflation and the downgrade of the Malta Government bonds.

The solvency ratio remains above 100% throughout the business planning period under this scenario.

## **C.7.7 Sensitivity Testing**

Sensitivity analysis assesses the impact of variations in experience. The aim of the analysis is to illustrate the sensitivity of the balance sheet to changes in different parameters. The stresses are applied as single-factor shocks on the current balance sheet, in contrast to the scenario analysis where interactions between risks are considered on the projected balance sheet.

Sensitivity of the current balance sheet to the following were performed:

#### Market Risks:

- Increase interest rates. The stress applied was a flat 100bps increase in interest rates at all durations
- Decrease in interest rates. The stress applied was a flat 50bps/100bps decrease in interest rates at all durations
- Reduction to the Ultimate Forward Rate by 100bps.
- A fall in the price of equities. The event considered is an immediate 25% fall in the value of equities
- A widening of credit spreads. The stress applied is 0.5% increase in the credit spread. A widening of the credit spread would depress bond values.

## Life underwriting risks:

- An increase in the Company's expenses. The stress applied was a 25% increase to the renewal expenses in perpetuity.
- A mass lapse event. The stress event is a mass lapse event where 40% of policies are lapsed or surrendered.
- A catastrophe claim event. Under this scenario 3% of protection policies are subject to a claim
- A stress on lapse rates. The stress applied is an increase in lapse rates of 50% on product lines which are profitable and a decrease in lapse rates of 50% on product lines which are not profitable.
- An increase in mortality and morbidity rates. The stress applied is an increase by 50%.

#### With-Profits Risks:

- Assuming there is no surplus within the with profit fund. Removing the surplus results in a greater
  cost of the guarantee and increased capital requirement as the cost of guarantees will now bite.
  This event could happen either through higher bonus declarations and/or negative investment
  returns.
- Assuming the surplus within the with profit fund is halved. This scenario is similar to the previous, however instead of eliminating the surplus, the surplus is halved.
- In a large number of cases, the stresses applied are similar to 1-in-200 levels. The information is used to make the management aware of the types of events that would impact the Company materially and to plan appropriate management actions to support the company solvency.

The sensitivities show that the Company reaches a Solvency Ratio of above 100% under all the scenarios.

However, the sensitivities show that the Company's solvency position is quite sensitive to the financial guarantees associated with the With-profits fund surplus under the current low interest rate environment. A decision was made to stop selling new business in 2021.

It is noted that some of the sensitivities are highly unlikely to materialise. For some of the market stresses, it may be likely that markets recover from a stress and therefore the stress is not sustained.

## **C.7.8 Liquidity Testing**

In addition to scenario testing of the solvency position there is also scenario testing on the Company's liquidity position. The purpose is to test the Company's liquidity over a twelve-month period. It was analysed by conducting different stresses and comparing the resulting net cash flow against the available liquid assets. During the exercise the following scenarios were used:

- Scenario 1: 1-month market wide stress A one month combined market wide and idiosyncratic (HSBC specific) scenario. The scenario considers a one-month situation where the market and customers significantly question the capital and liquidity position of HSBC relative to peers and where the market enters a period of extreme risk aversion and where these concerns abate after one month. The stress is expected to last for one month, with the market recovering over the next five months.
- Scenario 2: HSBC Specific Crisis. Loss of confidence in INMT due financial difficulties in non-INMT part of Group which results in a drop in equity values and immediate lapses.
- Scenario 3: 12-month market wide stress There is a significant slowdown in the global economy.
   Interest rates fall globally to restart faltering economies, equity markets fall and immediate lapses occurs.
- Scenario 4: With-profits Reserves Stress Test A reverse stress test has been performed to
  determine the maximum mass lapse shock that the With-Profits fund is able to withstand on day
  one based on the amount of liquid assets available in the With-Profits fund only i.e. before the level
  of liquid assets fall below the amount required to meet policyholder obligations.
- Scenario 5: Large Claims A stress test for large claims was conducted based on the top 5 policies with the largest sum assured to check if the current liquidity is able to withstand the claims.
- Scenario 6: Cyber Attack A stress test to determine how many months HSBC would be able to continue making payments in the case of a cyber-attack on systems preventing premium collections was carried out.

Note that there is no planned dividend over 2022. The liquidity scenario testing shows that the Company remains liquid throughout all scenarios identified. In addition, the reverse stress tests show that the Company is sufficiently liquid to withstand extreme events.

# C.8 Any other information

It should be noted that whilst some of the Covid 19 impacts on the financial markets have improved, the expectation is that the implications of the pandemic could continue to impact the Company over the longer term. Given this uncertainty, the assumptions used within the scenarios as part of the ORSA process are prudent and thus include the estimated impacts on the Company as a result of the Pandemic.

## D. Valuation for solvency purposes

#### **D.1** Assets

The Solvency II valuation of each material class of asset is presented in Section D.1.2 below.

## D.1.1 Bases, methods and main assumptions used in the valuation of the material classes of assets

#### **D.1.1.1 Investments**

The investments of the Company include the following financial asset classes:

- (a) Investments other than assets held for index linked and unit-linked funds include the following asset categories:
- government bonds;
- corporate bonds;
- listed equities;
- investment funds; and
- property (other than for own use).
- (b) Assets held for index-linked and unit-linked funds include the following asset categories (grouped together and shown as 'Assets held for index-linked and unit-linked contracts' in the Solvency II balance sheet):
- government bonds;
- corporate bonds;
- listed equities; and
- investment funds.

Investments in the Solvency II balance sheet are financial assets in terms of IFRS. All financial assets designated at fair value through profit or loss are managed, and their performance evaluated, on a fair value basis. For all financial instruments where fair values are determined by reference to externally quoted prices or observable pricing inputs to models, independent price determination or validation is utilised.

In inactive markets, direct observation of a traded price may not be possible. In these circumstances, the Company will source alternative market information to validate the financial instrument's fair value, with greater weight being placed on information that is considered to be more relevant and reliable. Further information on valuation of the assets using IFRS principles can be sourced from Note 3.9 "Financial instruments" of the Company's Audited Financial Statements for the year ended 31 December 2021.

As these assets are reported on a fair value basis in the IFRS financial statements, there are no adjustments required for Solvency II purposes, other than in relation to accrued interest. The Solvency II valuations include accrued interest receivable as at 31 December 2021, where applicable, whereas the accrued interest is classified with receivables in the IFRS financial statements.

There are no differences between the recognition and valuation bases for the assets and there have been no changes to the recognition and valuation bases for the assets.

As the assets are recognised and valued at fair value, the Company has not made any estimations, assumptions and judgments in this respect.

#### D.1.1.2 Reinsurance recoverables

Reinsurance recoverables represent the reinsurer's share of technical provisions and the valuation information is included in Section D.2 Technical Provisions below.

As the calculation of the reinsurance recoverables is based on the best estimate of future reinsurance claims less reinsurance premiums, the value of reinsurance recoverables is affected by the demographic and economic assumptions underlying the calculation of best estimate liabilities; particularly mortality, morbidity, lapse and interest rate assumptions. During 2021, lapse assumptions have been revised to reflect expected future experience. The interest rate assumptions have changed in line with the risk-free yield curve issued by EIOPA.

When deriving these assumptions, some judgements are necessary, for example determining what period of experience to analyse data over, how to group the data, what credibility criteria to apply to the data, and what assumptions to make in the absence of appropriate data.

#### D.1.1.3 Receivables

Receivables include the following asset classes:

- (a) Insurance & intermediaries receivables;
- (b) Reinsurance receivables; and
- (c) Receivables (trade, not insurance).

Receivables in the Solvency II balance sheet are financial assets in terms of IFRS. These receivables are classified as loans and receivables which are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market other than those that the Company, upon initial recognition, designates as at fair value through profit or loss. Financial assets are initially measured at fair value plus transaction costs that are directly attributable to their acquisition. Receivables are stated after initial recognition at amortised cost less impairment losses. The carrying amount of loans and receivables, including insurance receivables, is considered to be a reasonable approximation of their fair value.

There are no differences between the recognition and valuation bases for the receivables and there has been no changes to the recognition and valuation bases for the receivables.

The Company has not made any estimations, assumptions and judgments in this respect.

### D.1.1.4 Cash and cash equivalents

In the IFRS Financial Statements, cash and cash equivalents comprise cash balances and deposits with contractual maturity of less than three months. Subsequent to initial recognition, cash equivalents are measured at amortised cost, which is considered to equate to fair value.

Within Solvency II Balance Sheet, cash and cash equivalents comprise of cash and on demand deposits.

There are no differences between the value for the cash and cash equivalents and there has been no changes to the recognition and valuation bases for the cash and cash equivalents.

The Company has not made any estimations, assumptions and judgments in this respect.

# **D.1.1.5** Intangible Assets

The intangible assets of the Company comprise of the following items:

- (a) Present Value of In Force Business ("PVIF");
- (b) Computer Software; and
- (c) Deferred Acquisition Costs.
- (a) PVIF In the Company's IFRS Balance Sheet, a prudent valuation of future earnings that is expected to emerge from the life assurance in-force business is determined annually. The valuation represents the discounted value of projected future transfers to shareholders from life assurance in-force business, after adjusting for the effective rate of taxation. Assumptions relating to the future mortality, morbidity, persistency and expenses are used to calculate the PVIF and these are based on the experience of the type of business concerned. Gross investment returns assumed are based on the market risk-free rates which are derived from the Euro Swap Curve. Annual movements in the PVIF are recognised in the profit or loss.
- (b) Computer Software In the Company's IFRS Balance Sheet, acquired computer software is capitalised on the basis of the costs incurred to acquire and bring to use the specific software. These intangible assets are measured at cost less accumulated amortisation and any accumulated impairment losses. Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure is recognised in profit or loss as incurred. Amortisation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.
- (c) Deferred acquisition costs In the Company's IFRS Balance sheet, incremental costs that are incurred in acquiring investment management contracts and creditor protection business are deferred and amortised as the related revenue is recognised. All deferred acquisition costs are reviewed regularly to determine if they are recoverable from future cash flows on the associated contracts. Deferred acquisition costs that are not deemed to be recoverable are charged to profit or loss.

Under IFRS, deferred acquisition costs are amortised in profit or loss on a straight line basis over the estimated useful life of the contract.

None of these intangible assets are recognised for Solvency II purposes.

There has been no difference in the recognition and valuation bases for the intangibles.

The Company has not made any estimations, assumptions and judgments with respect to computer software and deferred acquisition costs.

The Company does not have any financial or operating leasing arrangements in place.

# **D.1.2** Material differences between the Solvency II and IFRS balance sheets

The table below shows the difference between the Solvency II and IFRS Balance Sheets:

	Solvency II value	IFRS value	Difference
Assets	(€000s)	(€000s)	(€000s)
Goodwill	(Goods)	(3333)	(3333)
Deferred acquisition costs		262	(262)
Intangible assets		34,097	(34,097)
Deferred tax assets		3 1,037	(3.1,03.7)
Pension benefit surplus			
Property, plant & equipment held for own use	2	2	
Investments (other than assets held for index-			
linked and unit-linked contracts)	328,743	326,720	2,023
Property (other than for own use)	1,600	1,600	-
Holdings in related undertakings, including	,	•	
participations			
Equities	15,240	15,240	
Equities - listed	15,240	15,240	
Equities - unlisted		•	
Bonds	268,381	266,386	1,995
Government Bonds	145,778	145,559	219
Corporate Bonds	122,603	120,827	1,776
Structured notes			
Collateralised securities			
Collective Investments Undertakings	43,522	43,494	28
Derivatives			
Deposits other than cash equivalents			
Other investments			
Assets held for index-linked and unit-linked	440.200	440.220	(22)
contracts	449,306	449,339	(33)
Loans and mortgages			
Loans on policies			
Loans and mortgages to individuals			
Other loans and mortgages			
Reinsurance recoverables from:	(19,949)	77,972	(97,921)
Non-life and health similar to non-life			
Non-life excluding health			
Health similar to non-life			
Life and health similar to life, excluding index-linked	(10.027)	77,972	(97,899)
and unit-linked	(19,927)	77,972	(97,699)
Health similar to life			
Life excluding health and index-linked and unit-	(19,927)	77,972	(97,899)
linked	(13,321)	11,312	(37,033)
Life index-linked and unit-linked	(22)	-	(22)
Deposits to cedants			
Insurance and intermediaries receivables		645	(645)
Reinsurance receivables	1,498		1,498
Receivables (trade, not insurance)	2,270	4,274	(2,004)
Own shares (held directly)			

Amounts due in respect of own fund items or initial fund called up but not yet paid in			
Cash and cash equivalents	33,849	33,849	
Any other assets, not elsewhere shown	8	-	8
Total assets	795,727	927,160	(131,433)

In view that the Company adopts IFRS as its financial reporting standards, there are no material differences between the Solvency II and IFRS balance sheet with the exception of the Solvency II adjustments outlined below.

## (a) Deferred acquisition costs:

Deferred acquisition costs are reported as nil in the Solvency II balance sheet as it has no residual value. They can only be recognised in the Solvency II balance sheet at a value other than nil if they can be sold separately and the Company can demonstrate that there is a value for the same or similar assets that has been derived from quoted market prices in active markets. In the Company's IFRS accounts they are accounted for using IFRS principles.

## (b) Intangible assets:

The IFRS accounts value represents the PVIF and computer software. Under Solvency II, these have nil value. They can only be recognised in the Solvency II balance sheet at a value other than nil if they can be sold separately and the Company can demonstrate that there is a value for the same or similar assets that has been derived from quoted market prices in active markets.

## (c) Investments (other than assets held for index-linked and unit-linked contracts):

For Solvency II purposes investment values include the balance of accrued interest income which is included in Receivables within the IFRS financial statements.

#### (d) Reinsurance recoverable:

The reinsurance recoverable (also known as the reinsurers' share of technical provisions) in the Solvency II balance sheet differs materially from the IFRS accounts. While under IFRS valuation principles, the technical reserves for life business are recognised in line with IFRS 4, this approach is materially different from the 'Best estimate of Technical Provisions' and 'Risk Margin' approach as required under Solvency II, which is detailed in Section D.2 below. The reinsurance recoverable is therefore adjusted in consequence of the adjustment. The reinsurers' share of technical provisions are also adjusted to reflect the probability of default of the counterparty and the resulting average loss (net technical provisions after the allowance for defaults).

#### **D.1.3 Off Balance Sheet items**

The Company does not have any off-balance sheet assets.

#### **D.2 Technical provisions**

#### D.2.1 Value of technical provisions and the bases, methods and main assumptions

## **D.2.1.1 Value of technical provisions**

The table below shows the breakdown of the technical provisions by the Solvency II lines of business as at 31st December 2021:

Line of Business	Bes	t Estimate Liab	ility	Risk	Total Net
	Gross	Reinsurance	Net	Margin	Technical Provisions
Life (excluding index-linked and unit-linked)	(€000s)	(€000s)	(€000s)	(€000s)	(€000s)
Protection	5,410	(19,927)	25,377	15,673	41,011
With-Profits	268,012	-	268,012	790	268,802
Index-linked & unit-linked					
Index-linked and Unit-linked	424,281	(22)	424,303	3,900	428,202
Total	697,703	(19,949)	717,652	20,363	738,015

## D.2.1.2 Methodology used to calculate the technical provisions

The methodology used to calculate the technical provisions is in line with the Commission Delegated Regulation (EU) 2015/35 (Delegated Regulation).

The value of technical provisions is calculated as the sum of the Best Estimate of technical Provisions (also known as the Best Estimate Liability ("BEL") and Risk Margin ("RM"), as described in the following sections).

## D.2.1.2.1 Best estimate of technical provisions

The approach taken to calculate the BEL is as follows:

The BEL is valued using a projection model on a policy-by-policy basis, with a provision for some homogeneous policy groupings being made outside the projection model due to these being less material.

Within the projection model, the expected future cash-flows for material items are projected for each policy for the duration of the policy. This includes items such as policyholder premiums, policyholder charges, policyholder claims from adverse events, maturity or surrender benefits, expenses and investment income.

The BEL is calculated on a gross of reinsurance basis as it is defined to exclude the risk mitigating effects from the reinsurance contracts. The cash flows relating to reinsurance (e.g. reinsurance premiums and claim recoveries) are used to calculate the reinsurance recoveries after allowing for a provision for reinsurer default.

The cash-flow projections are based on a number of assumptions which are summarised below. In general,

- the economic assumptions are set on a market-consistent basis.
- the non-economic assumptions (e.g. demographic and expense assumptions) are set on a best estimate basis such that there is an equal probability that experience is more or less favourable than assumed. This corresponds to a probability-weighted average of future cash-flows.

For each policy, cash-flows are summed for each month and then discounted back to the valuation date using the risk-free yield curve published by EIOPA (as referred to in Article 44 of the Delegated Regulation) for the calculation of technical provisions.

## D.2.1.2.2 Risk margin

The approach taken to calculate the RM is as follows:

The RM represents the amount that would theoretically have to be paid to another insurer (in addition to the BEL) to compensate them for taking over the insurance liabilities. It is based on the cost of capital held to support the risks which cannot be readily hedged.

The Delegated Regulation specifies that the RM should be calculated as the unhedgeable SCR in all future years multiplied by 6% (the cost-of-capital rate prescribed by EIOPA) and discounted at the risk-free yield curve published by EIOPA. All risks are considered other than the market risk module in the calculation of the unhedgeable SCR.

The use of simplifications is allowed by the Delegated Regulation to estimate future unhedgeable SCRs, as a full calculation is not justified by the scale and complexity of the business. The following methodology has been adopted:

- The capital requirement for each risk sub-module that currently makes up the unhedgeable SCR is taken.
- For less material risks, operational risk and counterparty default risk, the capital requirement for each risk in each future year is estimated using the current figure and appropriate risk drivers for scaling.
- For more significant risks, such as lapse risk, the capital requirement is projected in 5-year intervals and liner interpolation is used to estimate the figures annually.
- The unhedgeable SCR is calculated at the end of the first year, and every following year by aggregating the capital requirements for each of the risk in line with the Standard Formula correlations (as used in the aggregation of the SCR).
- Each year's SCR is multiplied by 6% in order to calculate the cost-of-capital in each future year.
- The future cost-of-capital figures are the discounted back to the valuation date using the risk-free yield curve published by EIOPA to give the RM.

## D.2.1.3 Assumptions used to calculate the technical provisions

The assumptions used in the cash-flow projections are as follows:

### **D.2.1.3.1** Economic assumptions

The economic assumptions used in the valuation basis are internally consistent and consistent with observable, reliable market data:

#### (a) Investment Return

The best estimate assumptions are set equal to the risk-free rates published by EIOPA quarterly.

## (b) Expense Inflation

The market-consistent estimates of future inflation are derived from the French inflation curve and weighted by the expected salary inflation within the Company. This reflects the proportion of the Company's expenses due to salary costs.

### (c) Reversionary Bonus rate

The level of future assumed reversionary bonuses varies in line with the change in the Investment Return assumption reflecting the 90:10 gate bonus philosophy and tax, where appropriate. As per the current bonus philosophy, the Company aims to distribute 75% of the 'Total distributable return' as reversionary bonus. Where the 'Total distributable return' equals Expected return earned on the fund based on the Investment Return assumption above less shareholder's share of investment return (10%) less withholding tax.

## (d) Discount Rates

The discount rates used are set equal to the risk-free rates published by EIOPA each month.

### D.2.1.3.2 Demographic assumptions

The principal demographic assumptions underlying the calculation of the insurance technical provisions are:

## 1. Mortality

A base mortality table is selected which is most appropriate for each type of contract. The mortality rates reflected in this table are adjusted to calculate the best estimate of the mortality assumptions based on the investigations that has been performed on determining the Company's mortality experience, where this is credible.

#### 2. Morbidity (Critical Illness)

An appropriate base table, based on the rate table produced by the Company's reinsurers, is selected for the Critical Illness contract. The rates reflected in this table are adjusted to calculate the best estimate of the morbidity assumptions based on the investigations that have been performed to determine the Company's morbidity experience, where this is credible.

### 3. Persistency

The Company's recent lapse experience is analysed for each major contract type and used to calculate the best estimate of the future persistency assumptions.

## 4. Renewal expenses

An investigation is performed to determine the current per policy renewal expenses and the appropriateness of this taking into account future in-force business volumes.

The Company holds additional Expense provisions as follows:

- A provision is held in relation to specific fixed expenses on an Investment portfolio that is in runoff. Judgements are taken in relation to the future management actions to reduce the fixed expenses in line the run-off of the portfolio.
- A provision is held for potential future expense shortfalls to allow for instances where the perpolicy costs are forecasted to be higher than current assumptions. This provision is reliant on the run-off of the in-force book and achieving the new business sales plan.

An explicit expense provision is held for IFRS 17 project related expenses due to the significance of the cost of implementation.

#### **D.2.1.3.3 Taxation**

The Company assumes that the application of current tax legislation will not change. However, the tax environment as it applies to life companies is complex and the application of the respective rules may result in varying interpretations. The directors consistently seek advice on various tax matters, however, there is a possibility that the final tax outcome differs from estimates made as part of the preparation of the financial statements. The directors do not consider that there is material tax exposure that has not been provided for, notwithstanding an element of uncertainty that may apply.

### D.2.1.4 Level of uncertainty associated with the value of technical provisions

Uncertainty primarily relates to how future actual experience will differ from the best estimate assumptions used to calculate the technical provisions. The key assumptions are interest rates, lapse rates, mortality rates, morbidity rates and expenses. The assumptions are reviewed annually, except for the risk-free rates which are updated quarterly, to ensure continued suitability. Any limitations and expert judgements are logged and monitored.

The balance sheet is also affected by volatility in the financial markets, for example the equity and bond markets. Where assets held on the balance sheet are affected, this may increase the value of technical provisions due to the cost of covering guarantees on the with-profits portfolio.

As further described in Note 4.1 to the Audited Financial statements, the main source of uncertainty is that epidemics such as AIDS, SARS, pandemic flu, swine flu, Covid 19 and wide-ranging lifestyle changes, such as in eating, smoking and exercise habits, could result in future mortality being significantly worse than in the past for the age groups in which the Company has significant exposure to mortality risk. The Company is also exposed to the volatility of the yield curve. These risks are heightened in the context of the current ongoing Covid 19 pandemic and the SFCR contains information pertaining to stress testing and sensitivity analysis performed by the Company. While over the short term the Covid 19 pandemic has not materially impacted the Company's mortality or lapse risk, it may have a longer term impact on mortality risk which is as yet undetermined or on lapses. New estimates are made each subsequent year to reflect the current long term outlook.

#### D.2.1.5 Material differences between the Solvency II and IFRS valuations

The financial statements for the Company are based on a different set of assumptions and methods. For the investment business, no technical provisions are held apart for the unit-linked liabilities and the financial statement ignores the PVIF on this line of business.

The technical provisions within the financial statements are based on the methodology underlying the Solvency I reserves prior to the implementation of the Solvency II. The assumptions used to calculate these reserves include a margin for prudence and the calculation method does not allow reserves to be negative or allow an assumption for persistency. In addition, the discount rates were derived from the investment assets supporting the liabilities subject to an adjustment for credit risk.

The PVIF reflects the expected future profit and the release of the reserves within the financial statements.

With the introduction of Solvency II from 1st January 2016 the technical provisions are calculated as the sum of the BEL, CoG and RM. If the with-profit fund is in surplus, the CoG reserve is held within the with-profit fund and does not form part of the technical provisions. However, if the with-profit fund is in deficit, part of CoG not supported by the with-profit fund is temporarily supported by the Company by increasing the technical provisions until the fund returns to surplus.

The BEL is calculated using the best estimate assumptions and the liabilities can be negative.

The key methodology differences are:

- (a) the removal of prudential margins in the assumptions and the move to best estimate assumptions under Solvency II and the allowance for negative reserves;
- (b) the requirement to hold a RM calculated using cost of capital approach; and
- (c) the deferred tax liability calculated as 35% of the difference in technical provisions net of reinsurance between the IFRS balance sheet and the SII balance sheet (including RM).

### D.2.1.6 Matching adjustment to the EIOPA risk-free interest rates

The Company does not apply the matching adjustment.

## D.2.1.7 Volatility adjustment to the EIOPA risk-free interest rates

The Company does not apply the volatility adjustment.

#### D.2.1.8 Transitional risk-free interest rate-term structure

The Company does not apply the transitional risk-free interest rate-term.

#### **D.2.1.9 Transitional deduction**

The Company does not apply the transitional deduction.

### D.2.1.10 Recoverables from reinsurance contracts and special purpose vehicles

The Company cedes reinsurance in the normal course of business for the purpose of limiting its net loss potential. Reinsurance arrangements do not relieve the Company from its direct obligations to its policyholders.

The reinsurance recoverables is the present value of the excess of the expected future reinsurance recoveries over the expected future reinsurance premiums payable.

The Company does not have any special purpose vehicles in place.

## D.2.1.11 Material changes in assumptions made in the calculation of technical provisions

There are no material changes in the relevant assumptions used to calculate the technical provisions when compared to the previous reporting period.

### **D.2.1.12 Off Balance Sheet items**

The Company does not have any off-balance sheet liabilities.

## **D.3 Other liabilities**

The Solvency II valuation of each material class of liability is presented in section D.3.3 below.

## D.3.1 Value of other liabilities, excluding technical provisions

The other liabilities of the Company other than technical provisions comprise the following items:

- 1. Deferred tax liabilities;
- 2. Payables; and
- 3. Provision for liabilities and charges.

# D.3.2 Methods and assumptions used in the valuation of other liabilities, excluding technical provisions

## D.3.2.1 Deferred tax liabilities

The deferred tax liabilities are recognised on the temporary differences between the carrying amounts of assets and liabilities in the IFRS balance sheet and the amounts attributed to such assets and liabilities for tax purposes. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax liabilities are generally recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which deductible temporary differences can be utilised. Section D.3.3.1 contains further information on the SII valuation basis.

## D.3.2.2 Payables

The payables of the Company comprise the following items:

- (a) Insurance & intermediaries payables;
- (b) Reinsurance payables; and
- (c) Payables (trade, not insurance).

Payables are stated at amortised cost in the IFRS financial statements which is deemed to be a reasonable approximation of the fair value and thus no valuation adjustment is required for solvency purposes.

There has been no difference in the recognition and valuation bases for the other liabilities and there has been no changes to the recognition and valuation bases for the other liabilities.

The Company has not made any estimations, assumptions and judgments in this respect.

There are no restrictions on, deductions from or encumbrances on the own funds of the Company.

## D.3.2.3 Provision for liabilities and charges

A provision for contingent liabilities and charges is recognised when it is probable that an outflow of economic benefits will be required to settle a present legal or constructive obligation that has arisen as a result of past events and for which a reliable estimate can be made.

The Company holds a provision in relation to an onerous contract which results from a closed investment product where related income is based on balances under management, whilst related costs are predominantly fixed. The provision for liabilities and charges represents an estimate of future losses and is substantially not current in nature. Provision for liabilities and charges are presented in Note 22 in the Audited Financial Statements.

This provision was classified within technical provisions in the Solvency II Balance Sheet, and valued in accordance with Section D.2.

## D.3.3 Material differences between the Solvency II and IFRS Balance Sheet

	Solvency II value	IFRS value	Difference
Liabilities	(€000s)	(€000s)	(€000s)
Technical provisions - non-life	-	-	-
Technical provisions - non-life (excluding health)	-	-	-
TP calculated as a whole	-	-	-
Best Estimate	1	-	-
Risk margin	1	1	-
Technical provisions - health (similar to non- life)	-	-	-
TP calculated as a whole	-	-	-
Best Estimate	-	-	-
Risk margin	-	-	-
Technical provisions - life (excluding index- linked and unit-linked)	289,885	394,011	(104,126)
Technical provisions - health (similar to life)	-	-	-

	Solvency II value	IFRS value	Difference
TP calculated as a whole	-	-	-
Best Estimate	-	-	-
Risk margin	-	-	-
Technical provisions - life (excluding health	289,885	394,011	(104,126)
and index-linked and unit-linked)	203,003	394,011	(104,120)
TP calculated as a whole	-	-	-
Best Estimate	273,422	-	273,422
Risk margin	16,463	-	16,463
Technical provisions - index-linked and unit-	428,181	449,323	(21,142)
linked	420,101	443,323	(21,142)
TP calculated as a whole	-	-	-
Best Estimate	424,281	-	424,281
Risk margin	3,900	-	3,900
Other technical provisions	-	-	-
Contingent liabilities	-	-	-
Provisions other than technical provisions		1	(1)
Pension benefit obligations	-	-	-
Deposits from reinsurers	-	-	-
Deferred tax liabilities	8,507	11,356	(2,849)
Derivatives	-	-	-
Debts owed to credit institutions	-	-	-
Debts owed to credit institutions resident	-	-	-
domestically			
Debts owed to credit institutions resident in	-	-	-
the euro area other than domestic			
Debts owed to credit institutions resident in	-	-	-
rest of the world			
Financial liabilities other than debts owed to	-	-	-
credit institutions			
Debts owed to non-credit institutions	-	-	-
Debts owed to non-credit institutions	-	-	-
resident domestically			
Debts owed to non-credit institutions	-	-	-
resident in the euro area other than			
domestic			
Debts owed to non-credit institutions resident in rest of the world	-	-	-
Other financial liabilities (debt securities			
issued)	-	-	-
Insurance & intermediaries payables	5,989	3,260	2,729
Reinsurance payables	1,426	134	1,292
Payables (trade, not insurance)	3,573	5,557	(1,984)
Subordinated liabilities	-	-	
Subordinated liabilities not in BOF	-	-	
Subordinated liabilities in BOF	-	-	
Any other liabilities, not elsewhere shown	-	41	(41)
Total liabilities	737,561	863,682	(134,238)

#### D.3.3.1 Deferred tax

Any adjustments made to the IFRS balance sheet for the purpose of Solvency II reporting should be considered for potential related deferred tax adjustments. The adjustments represent the tax effect of the valuation differences between the IFRS basis and the Solvency II basis namely the PVIF, technical provisions and reinsurance. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date.

#### D.4 Alternative methods for valuation

For Solvency II purposes, no alternative methods of valuation have been used to value the assets and liabilities aside from those described in the Section D.1.1 above.

#### **D.5 Other information**

There continues to be heightened market volatility in the current environment given the ongoing Covid 19 pandemic and the conflict in Ukraine conflict which may impact the Company's solvency position. Indeed, subsequent to the reporting date, economic sanctions have been imposed by other countries against Russia and Belarus. The conflict in Ukraine elevated uncertainty and instability on the global economic scene and global markets in early 2022 and, most likely, will intensify the rise in inflation, especially if prolonged. The Company has limited direct exposure to assets in those jurisdictions and concluded that there should not be material consequences to the Company's solvency position given the minimal investment holdings associated with the countries involved. Nonetheless, the precise nature and effect of such a conflict, including any indirect impacts through adverse consequences on the local economy and wider financial markets, cannot be determined at this stage. The Company does have a suite of sensitivities to changes in market conditions, some of which have material impacts on the Company's solvency position but they do not prevent it from being a going concern. The Company is following and shall continue to follow closely how such events will develop. The directors consider the going concern assumption to remain appropriate on the basis of information known to date.

## E. Capital management

#### E.1 Own funds

## E.1.1 Objectives, policies and processes employed for managing its own funds

The Company must hold a buffer over the SCR, for the following reasons:

- (a) To enable it to write new business, that is to meet the development costs of new contracts and the capital requirements from writing new business;
- (b) To ensure solvency (without need for capital injection) on an ongoing basis withstanding ordinary volatility in economic and non-economic experience, and in the event of mild stress scenarios; and
- (c) To protect against regulatory intervention.

The optimum level of capital buffer ensures that:

- (a) A capital injection is not required over the planning time horizon with an acceptable confidence level; and
- (b) Excess capital is not sitting with the Company reducing return on capital to the shareholders.

The SCR and MCR for the company is derived using EIOPA's Standard Formula for the assessment of all risks.

## E.1.1.1 Triggers for reviewing the Capital Management Framework

If at any point there are material changes in the Solvency II reporting basis, or in the Company's strategy, or material deviations from the Financial Resources Plan ("FRP"), then dividends should be put on hold and this policy reviewed. It should also be reviewed and approved by the Board on an annual basis.

## E.1.1.2 Capital planning period

The business' capital planning period is 5 years.

### E.1.1.3 Material changes

There were no material changes in the objectives, policies and processes employed for managing own funds. As part of the Capital Management Framework annual review, the target capital level was updated in line with the business' 5 year plans.

## E.1.2 Structure, amount and quality of own funds

The Company's Own Funds as at 31 December 2021 comprised only of Tier 1 Basic Own Funds, with no Ancillary Own Funds requiring regulatory approval.

The table below summarises the structure of the Company's basic own funds at 31 December 2021 and 2020:

Basic own funds (Tier 1 and Tier 2)  2021  €'000	2021	2020	Difference
	€′000	€′000	
Ordinary share capital – Tier 1	27,961	27,961	-
Reconciliation reserve – Tier 1	30,205	30,638	(433)
Total – Excess of assets over liabilities	58,166	58,599	(433)

The Basic own funds have fallen by €0.4m during the year driven by the fall in yields and changes to the assumptions during the Basis Review.

The analysis of change for each tier is summarised below:

#### E.1.2.1 Basic own funds

## (a) Ordinary share capital (Tier 1)

The Company's ordinary share capital possesses the characteristics as prescribed in Article 71 of the Regulation to be classified as Tier 1 Basic Own Fund items under Solvency II.

There has been no change in the amount of the paid-up ordinary share capital of the Company.

## (b) Reconciliation reserve: Excess of assets over liabilities (Tier 1)

The reconciliation reserve consists of excess of assets over liabilities less ordinary share capital. The excess of assets over liabilities is considered to be free from encumbrances and any foreseeable liabilities and is readily available to absorb losses arising from adverse business fluctuations, both on a going-concern basis as well as in the case of winding-up and thus is classified as Tier 1 Basic Own Funds.

The reconciliation reserve arises from the difference in the technical provisions and the reinsurance share of technical provisions (reinsurance recoverables) calculated under Solvency II and IFRS. The changes in the reconciliation reserve from the previous reporting period arises from the difference in the technical provisions and the reinsurance share of technical provisions from the previous reporting year.

The reconciliation reserve comprises differs from retained earnings in terms of IFRS as a consequence of the difference between the Company's IFRS net assets and the Solvency II excess of assets over liabilities. The tables presented in Section D present the valuation differences for each material class of asset and liability.

## E.1.3 Eligible own funds to cover the SCR and MCR

The table below summarises the Company's Eligible Own Funds used to cover the SCR and MCR at 31 December 2021 and 2020:

Elizible over funds	2021	2020	Difference
Eligible own funds	€′000	€′000	€′000
Ordinary share capital – Tier 1	27,961	27,961	-
Reconciliation reserve – Tier 1	30,205	30,638	(433)
Excess of assets over liabilities	58,166	58,599	(433)
SCR	27,966	32,401	(4,440)
MCR	10,858	10,904	(46)
Ratio of Eligible own funds to SCR	208%	181%	27%
Ratio of Eligible own funds to MCR	536%	537%	(1%)

The Company's basic own fund items are all eligible to cover the SCR and MCR in view that they are Tier 1 Basic Own Fund items.

# E.1.4 Material differences between Equity under IFRS and the Excess of assets over liabilities under Solvency II

## E.1.4.1 Equity versus Excess of assets over liabilities

The table below summarises the difference between the total shareholders' equity in the IFRS statutory accounts and the Excess of assets over liabilities for solvency purposes at 31 December 2021 and 2020:

	2021	2020	Difference
IFRS versus Solvency II	€'000	€'000	€'000
Total shareholders' equity IFRS	63,478	65,398	(1,920)
Solvency II adjustments	(5,312)	(6,799)	1,487
Excess of assets over liabilities	58,166	58,599	(433)

Refer to Section D.1, D.2 and D.3 above for the material Solvency II adjustments that have been made.

### **E.1.5 Transitional arrangements**

The Company has not applied any transitional arrangements.

## E.1.6 Ancillary own funds

The Company does not currently have any ancillary own funds.

## E.1.7 Significant restriction affecting the availability and transferability of own funds

The Company does not deduct any items from own funds and has no restrictions on the availability and transferability of its own funds as it is all Tier 1.

## E.1.8 Own fund ratios

The Company does not disclose any ratios in addition to the SCR and MCR ratios presented in S.23.01.01 in Appendix 1.

## E.1.9 Principal loss absorbency mechanism and trigger point

The principal loss absorbency mechanisms ("PLAM") and trigger point in terms of paragraph (1) (e) of Article 71 of the Delegated Regulations only applies to the following own funds items:

- (a) paid-in subordinated mutual member accounts;
- (b) paid-in preference shares and the related share premium account; and
- (c) paid-in subordinated liabilities.

In view that the Company's strategy is to hold Tier 1 Basic Own Fund Items and does not make use of any of the own funds items listed above, the PLAM and related trigger points are not currently of significant importance.

## E.1.10 Loss absorbing capacity of deferred tax

The loss absorbing capacity of deferred tax reduces the capital requirement for each risk. The reduction is estimated using the corporation tax rate of 35% and the gross of tax capital requirement for each risk. In 2021, a tax agreement was signed between the Company and its parent's Company which gives the

Company the ability to fully recognise the loss absorbing capacity of deferred taxes in the Solvency Capital Requirement calculation.

As the result of the removing of the capping, the LACDT increased from €10m (i.e it was capped by €4.8m) to 15.1m improving the Solvency ratio upwards by 40 points.

## **E.2 Solvency Capital Requirement and Minimum Capital Requirement**

## E.2.1 Solvency and Minimum Capital Requirement as at 31 December 2021

The SCR and MCR of the Company as at 31 December 2021 is presented in the table below:

	2021
	€′000
SCR	27,966
MCR	10,858

There are no balances relating to the SCR and MCR which are currently under supervisory assessment.

# E.2.1.1 Solvency Capital Requirement as at 31 December 2021 split by risk modules

The breakdown of the SCR by risk modules as calculated by the Standard Formula is presented in the table below:

Risk Module	2021	2020
	Net	Net
	€′000	€′000
Market Risk	17,106	18,240
Counterparty Default Risk	6,997	1,221
Life Underwriting Risk	30,850	31,846
Health Underwriting Risk	-	-
Undiversified BSCR	54,953	51,307
Diversification	(13,420)	(10,449)
BSCR	41,533	40,858
Operational Risk	1,492	1,494
SCR before the Loss absorbing capacity of deferred taxes	43,025	42,352
Loss absorbing capacity of deferred taxes	(15,059)	(9,952)
SCR after the Loss absorbing capacity of deferred taxes	27,966	32,401

Market Risk decreases mainly due to the decrease of the capital required to support the cost of guarantees on the With-Profits book under stress due to an increase in the fund surplus.

The Credit Capital Risk measurement has increased over the year, mainly driven by the categorisation of the cash position held with counterparties to unrated.

The Company does not use an internal model or undertaking-specific parameters to calculate the SCR.

The increase of the Loss absorbing capacity of deferred taxes was primarily driven by the tax agreement signed between the Company and its parent's Company which gives the Company the ability to fully recognise the loss absorbing capacity of deferred taxes in the Solvency Capital Requirement calculation; last year, the Company conservatively capped its loss absorbing capacity of deferred taxes to €4.8m.

The deferred tax liabilities used by the company to demonstrate likely utilisation pertain primarily to the change of the Technical Reserves in IFRS and BEL.

## E.2.1.2 Simplified calculations used for standard formula

No simplifications have been used to calculate the SCR under the standard formula.

## E.2.1.3 Undertaking- specific parameters used for standard formula calculations

No undertaking-specific parameters have been used to calculate the SCR under the standard formula calculations.

## E.2.1.4 Capital add-on

The Company is not required to hold any additional regulatory capital add-on.

### **E.2.1.5 Minimum Capital Requirement inputs**

The MCR is calculated using the method prescribed by the Solvency II EU Commission Delegated Regulations 2015/35. The inputs used in this calculation are detailed below:

- (a) With-profit obligations relating to the guaranteed benefits;
- (b) With-profit obligations relating to the discretionary benefits;
- (c) Unit-linked obligations;
- (d) Total Capital at risk for all life insurance obligations, after allowing for reinsurance; and
- (e) SCR.

The BEL for non-linked products is set to a minimum of zero in order to avoid reducing the MCR, in line with the EU Commission Delegated Regulations 2015/35.

# E.2.1.6 Material change to the Solvency Capital Requirement and to the Minimum Capital Requirement

The table below summarised the SCR and MCR as at December 2021 and 2020:

	2021	2020
	€′000	€′000
SCR	27,966	32,401
MCR	10,858	10,904

The table above shows that there has been an increase in the SCR over the reporting period as detailed in sections C0 to C3 and E 2.1.1.

# E.3 Use of the duration-based equity risk sub-module in the calculation of the solvency capital requirement

Duration-based equity risk sub-module has not been applied in the calculation of the SCR.

#### E.4 Difference between the standard formula and internal model used

The Company does not currently use an internal model to calculate the SCR.

## E.5 Non-compliance with minimum capital and solvency capital requirements

The Company has complied with both the SCR and MCR during the year. The ORSA report also shows that the Company will continue to comply with the SCR and MCR through the business planning period.

## **E.6** Any other information

There continues to be heightened market volatility in the current environment given the ongoing Covid 19 pandemic and the conflict in Ukraine conflict which may impact the Company's solvency position. Indeed, subsequent to the reporting date, economic sanctions have been imposed by other countries against Russia and Belarus. The conflict in Ukraine elevated uncertainty and instability on the global economic scene and global markets in early 2022 and, most likely, will intensify the rise in inflation, especially if prolonged. The Company has limited direct exposure to assets in those jurisdictions and concluded that there should not be material consequences to the Company's solvency position given the minimal investment holdings associated with the countries involved. Nonetheless, the precise nature and effect of such a conflict, including any indirect impacts through adverse consequences on the local economy and wider financial markets, cannot be determined at this stage. The Company does have a suite of sensitivities to changes in market conditions, some of which have material impacts on the Company's solvency position but they do not prevent it from being a going concern. The Company is following and shall continue to follow closely how such events will develop. The directors consider the going concern assumption to remain appropriate on the basis of information known to date.

# Appendix I: Quantitative reporting templates ("QRTs")

- (a) S.02.01.02 Balance Sheet
- (b) S.05.01.02 Premiums, claims and expenses by line of business
- (c) S.05.02.01 Premiums, claims and expenses by country
- (d) S.12.01.02 Life Technical Provisions
- (e) S.23.01.01 Own Funds
- (f) S.25.01.21 Solvency Capital Requirement for undertakings on Standard Formula
- (g) S.28.01.01 Minimum Capital Requirement

# SE.02.01.16

### **Balance sheet**

# Assets

#### R0010 Goodwill R0020 Deferred acquisition costs R0030 Intangible assets R0040 Deferred tax assets R0050 Pension benefit surplus R0060 Property, plant & equipment held for own use R0070 Investments (other than assets held for index-linked and unit-linked contracts) R0080 Property (other than for own use) Holdings in related undertakings, including participations R0090 R0100 **Equities** Equities - listed R0110 R0120 Equities - unlisted R0130 Bonds R0140 **Government Bonds** R0150 Corporate Bonds R0160 Structured notes R0170 Collateralised securities R0180 Collective Investments Undertakings R0190 Derivatives R0200 Deposits other than cash equivalents R0210 Other investments R0220 Assets held for index-linked and unit-linked contracts R0230 Loans and mortgages Loans on policies R0240 Loans and mortgages to individuals R0250 R0260 Other loans and mortgages

# Solvency II value

### C0010

0.00
0.00
0
0
0
2
328,743
1,600
0
15,240
15,240
0
268,381
145,778
122,603
0
0
43,521
0
0
0
449,306
0
0
0
0

R0270 Reinsurance recoverables from:	-19,949
R0280 Non-life and health similar to non-life	0
R0290 Non-life excluding health	0
R0300 Health similar to non-life	0
R0310 Life and health similar to life, excluding index-linked and unit-linked	-19,927
R0320 Health similar to life	0
R0330 Life excluding health and index-linked and unit-linked	-19,927
R0340 Life index-linked and unit-linked	-22
R0350 Deposits to cedants	0
R0360 Insurance and intermediaries receivables	0
R0370 Reinsurance receivables	1,498
R0380 Receivables (trade, not insurance)	2,270
R0390 Own shares (held directly)	0
R0400 Amounts due in respect of own fund items or initial fund called up but not yet paid in	0
R0410 Cash and cash equivalents	33,849
R0420 Any other assets, not elsewhere shown	8
R0500 Total assets	795,727
R0500 Total assets	795,727
R0500 Total assets	
R0500 Total assets	Solvency II value
	Solvency II value
Liabilities	Solvency II value
Liabilities R0510 Technical provisions - non-life	Solvency II value  C0010
Liabilities  R0510 Technical provisions - non-life  R0520 Technical provisions - non-life (excluding health)	Solvency II value  C0010  0 0
Liabilities  R0510 Technical provisions - non-life  R0520 Technical provisions - non-life (excluding health)  R0530 TP calculated as a whole	Solvency II value  C0010  0 0 0
Liabilities  R0510 Technical provisions - non-life  R0520 Technical provisions - non-life (excluding health)  R0530 TP calculated as a whole  R0540 Best Estimate	Solvency II value  C0010  0 0 0 0
Liabilities  R0510 Technical provisions - non-life  R0520 Technical provisions - non-life (excluding health)  R0530 TP calculated as a whole  R0540 Best Estimate  R0550 Risk margin	Solvency II value  C0010  0 0 0 0 0
Liabilities  R0510 Technical provisions - non-life  R0520 Technical provisions - non-life (excluding health)  R0530 TP calculated as a whole  R0540 Best Estimate  R0550 Risk margin  R0560 Technical provisions - health (similar to non-life)	Solvency II value  C0010  0 0 0 0 0 0
Liabilities  R0510 Technical provisions - non-life  R0520 Technical provisions - non-life (excluding health)  R0530 TP calculated as a whole  R0540 Best Estimate  R0550 Risk margin  R0560 Technical provisions - health (similar to non-life)  R0570 TP calculated as a whole	Solvency II value  C0010  0 0 0 0 0 0 0
Liabilities  R0510 Technical provisions - non-life  R0520 Technical provisions - non-life (excluding health)  R0530 TP calculated as a whole  R0540 Best Estimate  R0550 Risk margin  R0560 Technical provisions - health (similar to non-life)  R0570 TP calculated as a whole  R0580 Best Estimate	Solvency II value  C0010  0 0 0 0 0 0 0 0 0 0
Liabilities  R0510 Technical provisions - non-life  R0520 Technical provisions - non-life (excluding health)  R0530 TP calculated as a whole  R0540 Best Estimate  R0550 Risk margin  R0560 Technical provisions - health (similar to non-life)  R0570 TP calculated as a whole  R0580 Best Estimate  R0590 Risk margin	Solvency II value  C0010  0 0 0 0 0 0 0 0 0 0 0 0 0
Liabilities  R0510 Technical provisions - non-life  R0520 Technical provisions - non-life (excluding health)  R0530 TP calculated as a whole  R0540 Best Estimate  R0550 Risk margin  R0560 Technical provisions - health (similar to non-life)  R0570 TP calculated as a whole  R0580 Best Estimate	Solvency II value  C0010  0 0 0 0 0 0 0 0 0 0

R0620 TP calculated as a whole	0
R0630 Best Estimate	0
R0640 Risk margin	0
R0650 Technical provisions - life (excluding health and index-linked and unit-linked)	289,885
R0660 TP calculated as a whole	0
R0670 Best Estimate	273,422
R0680 Risk margin	16,463
R0690 Technical provisions - index-linked and unit-linked	428,181
R0700 TP calculated as a whole	0
R0710 Best Estimate	424,281
R0720 Risk margin	3,900
R0730 Other technical provisions	0
R0740 Contingent liabilities	0
R0750 Provisions other than technical provisions	0
R0760 Pension benefit obligations	0
R0770 Deposits from reinsurers	0
R0780 Deferred tax liabilities	8,507
R0790 Derivatives	0
R0800 Debts owed to credit institutions	0
ER0801 Debts owed to credit institutions resident domestically	0
ER0802 Debts owed to credit institutions resident in the euro area other than domestic	0
ER0803 Debts owed to credit institutions resident in rest of the world	0
R0810 Financial liabilities other than debts owed to credit institutions	0
ER0811 Debts owed to non-credit institutions	0
ER0812 Debts owed to non-credit institutions resident domestically	0
ER0813 Debts owed to non-credit institutions resident in the euro area other than domestic	0
ER0814 Debts owed to non-credit institutions resident in rest of the world	0
ER0815 Other financial liabilities (debt securities issued)	0
R0820 Insurance & intermediaries payables	5,989
R0830 Reinsurance payables	1,426
R0840 Payables (trade, not insurance)	3,573
R0850 Subordinated liabilities	0
R0860 Subordinated liabilities not in BOF	0

R0870 Subordinated liabilities in BOF	0
R0880 Any other liabilities, not elsewhere shown	0
R0900 Total liabilities	737,561
R1000 Excess of assets over liabilities	58,166

S.05.01.01
Premiums, claims and expenses by line of business

	Premiums, claims and expenses by line of business	P				1
	Life					
		Health insurance	Insurance with profit participation	Index-linked and unit- linked insurance	Other life insurance	Total
		C0210	C0220	C0230	C0240	C0300
	Premiums written					
R1410	Gross		13,461	35,775	14,858	64,093
	Reinsurers' share				5,738	5,738
R1500		0.00	13,461	35,775	9,119	58,355
54540	Premiums earned		40.464	05.775	44.040	54.004
R1510			13,461	35,775	14,849	64,084
	Reinsurers' share	0.00	12.461	0	5,741 9,107	5,741
R1600	Claims incurred	0.00	13,461	35,775	9,107	58,343
R1610			27,408	38,775	2,683	68,866
	Reinsurers' share		27,400	30,773	2,083	2,097
R1700		0.00	27,408	38,775	586	66,769
	Changes in other technical provisions		,			,
R1710			-12,058	35,704	-1,196	22,450
R1720	Reinsurers' share				-1,760	-1,760
R1800	Net	0.00	-12,058	35,704	564	24,210
R1900	Expenses incurred	0.00	1,283	3,007	4,209	8,499
D4040	Administrative expenses		4 202	2 207	2.462	7.4.42
R1910	Reinsurers' share		1,283	2,397	3,462	7,142 0
R2000		0.00	1,283	2,397	3,462	7,142
K2000	Investment management expenses	0.00	1,203	2,337	3,402	7,142
R2010			0	-35	-43	-78
	Reinsurers' share		-			0
R2100		0.00	0	-35	-43	-78
	Claims management expenses					
R2110	Gross					0
R2120	Reinsurers' share					0
R2200		0.00	0	0	0	0
	Acquisition expenses			I		
R2210			0	646	790	1,436
	Reinsurers' share	0.00	0	646	700	0
R2300	Overhead expenses	0.00	0	646	790	1,436
R2310	•					0
	Reinsurers' share					0
R2400		0.00	0	0	0	0
	Other expenses					
	Total expenses					8,499
R2700	Total amount of surrenders		6,848	17,103		23,952

S.05.02.01
Premiums, claims and expenses by country

	-	00100	00100	00170	00100	00100	00200	00220
	Life	Hamas Caumbur.	Top 5 countries (by amount of gross premiums written) - life obligations			ns	Total Top 5 and	
R1400		Home Country	United Kingdom	South Africa	Viet Nam	China	Singapore	home country
	L	C0220	C0230	C0240	C0250	C0260	C0270	C0280
	Premiums written							
R1410	Gross	63,513	710	111	76	36	50	64,496
R1420	Reinsurers' share							0
R1500	Net	63,513	710	111	76	36	50	64,496
	Premiums earned							
R1510	Gross	63,504						63,504
R1520	Reinsurers' share							0
R1600	Net	63,504	0	0	0	0	0	63,504
	Claims incurred							
R1610	Gross	61,001	4,416	687	0	13	0	66,117
R1620	Reinsurers' share	0						0
R1700	Net	61,001	4,416	687	0	13	0	66,117
	Changes in other technical provisions							
R1710	Gross	48,239	-1,196	-1,037	-75	392	-81	46,242
R1720	Reinsurers' share	1,760						1,760
R1800	Net	46,479	-1,196	-1,037	-75	392	-81	44,482
	-	T.						
	Expenses incurred	8,499						8,499
	Other expenses							
R2600	Total expenses							8,499

C0170

C0180

C0190

C0200

C0210

C0160

C0150

#### S.12.01.01

Life and Health SLT Technical Provisions

	Insurance with profit participation		Contracts without options and guarantees	Contracts with options or guarantees		Contracts without options and guarantees	Contracts with options or guarantees	Total (Life other than health insurance, incl Unit-linked)
R0010 Technical provisions calculated as a whole R0020 Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP calculated as a whole Technical provisions calculated as a sum of BE and RM	C0020	C0030	C0040	C0050	C0060	C0070	C0080	0.00 0.00
Best estimate R0030 Gross Best Estimate	268,012	l [	424,281		]	5,410		697,703
RO040 Total recoverables from reinsurance/SPV and Finite Re before the adjustment for expected losses due to counterparty default RO050 Recoverables from reinsurance (except SPV and Finite Re) before adjustment for expected losses RO070 Recoverables from Finite Re before adjustment for expected losses RO070 Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default RO090 Best estimate minus recoverables from reinsurance/SPV and Finite Re	268,012		-22 424,303	0		-19,927 25,337	0	0 0 0 0 -19,949 717,652
R0100 Risk margin	790	3,900			15,673	]		20,363
Amount of the transitional on Technical Provisions  R0110 Technical Provisions calculated as a whole  R0120 Best estimate  R0130 Risk margin  R0200 Technical provisions - total  R0210 Technical provisions minus recoverables from reinsurance/SPV and Finite Re - total  R0220 Best estimate of products with a surrender option	268,802 268,802	428,181 428,203			21,084 41,010			0.00 0.00 0.00 718,066 738,015
Gross BE for cash flow Cash out-flows  R0230 Future guaranteed and discretionary benefits R0240 Future guaranteed benefits R0250 Future discretionary benefits R0260 Future expenses and other cash out-flows Cash in-flows  R0270 Future premiums Other cash in-flows Other cash in-flows						] ]		0.00 0.00 0.00 0.00 0.00
R0290 Percentage of gross Best Estimate calculated using approximations						]		
R0310 Surrender value  R0310 Best estimate subject to transitional of the interest rate R0320 Technical provisions without transitional on interest rate R0330 Best estimate subject to volatility adjustment R0340 Technical provisions without volatility adjustment and without others transitional measures R0350 Best estimate subject to matching adjustment R0360 Technical provisions without matching adjustment and without all the others								0.00 0.00 0.00 0.00 0.00 0.00

Index-linked and unit-linked insurance

Other life insurance

#### S.23.01.01

#### Own Funds

#### Basic own funds before deduction for participations in other financial sector as foreseen in article 68 of Delegated Regulation 2015/35

R0010 Ordinary share capital (gross of own shares)

R0030 Share premium account related to ordinary share capital

R0040 Initial funds, members' contributions or the equivalent basic own-fund item for mutual and mutual-type undertakings

R0050 Subordinated mutual member accounts

R0070 Surplus funds

R0090 Preference shares

R0110 Share premium account related to preference shares

R0130 Reconciliation reserve

R0140 Subordinated liabilities

R0160 An amount equal to the value of net deferred tax assets

R0180 Other own fund items approved by the supervisory authority as basic own funds not specified above

#### Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds

R0220 Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds

#### Deductions

R0230 Deductions for participations in financial and credit institutions

#### R0290 Total basic own funds after deductions

#### Ancillary own funds

R0300 Unpaid and uncalled ordinary share capital callable on demand

R0310 Unpaid and uncalled initial funds, members' contributions or the equivalent basic own fund item for mutual and mutual - type undertakings, callable on demand

R0320 Unpaid and uncalled preference shares callable on demand

R0330 A legally binding commitment to subscribe and pay for subordinated liabilities on demand

R0340 Letters of credit and guarantees under Article 96(2) of the Directive 2009/138/EC

R0350 Letters of credit and guarantees other than under Article 96(2) of the Directive 2009/138/EC

R0360 Supplementary members calls under first subparagraph of Article 96(3) of the Directive 2009/138/EC

R0370 Supplementary members calls - other than under first subparagraph of Article 96(3) of the Directive 2009/138/EC

R0390 Other ancillary own funds

R0400 Total ancillary own funds

#### Available and eligible own funds

R0500 Total available own funds to meet the SCR

R0510 Total available own funds to meet the MCR

R0540 Total eligible own funds to meet the SCR

R0550 Total eligible own funds to meet the MCR

R0580 SCR

R0600 MCR

 $R0620\;$  Ratio of Eligible own funds to SCR

R0640 Ratio of Eligible own funds to MCR

#### Reconciliation reserve

R0700 Excess of assets over liabilities

R0710 Own shares (held directly and indirectly)

R0720 Foreseeable dividends, distributions and charges

R0730 Other basic own fund items

R0740 Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds

R0760 Reconciliation reserve

Total	Tier 1 unrestricted	Tier 1 restricted	Tier 2	Tier 3
C0010	C0020	C0030	C0040	C0050
27,961	27,961			
0				
0				
0				
0				
0				
0				
30,205	30,205			
0		•		
0				
0		•		

0				
-				
58,166	58,166	0.00	0.00	0.00

0.00		
0.00		
0.00		
0.00		
0.00		
0.00		
0.00		
0.00		
0.00		
0.00	0.00	0.00

58,166	58,166	0.00	0.00	0.00
58,166	58,166	0.00	0.00	
58,166	58,166	0.00	0.00	0.00
58,166	58,166	0.00	0.00	

27,966
10,858
208%
536%

C0060

58,16
27,96
30,20

#### **Expected profits**

R0770 Expected profits included in future premiums (EPIFP) - Life business

R0780 Expected profits included in future premiums (EPIFP) - Non- life business

R0790 Total Expected profits included in future premiums (EPIFP)

21,690
21.690

#### S.25.01.01

Z0010

#### Solvency Capital Requirement - for undertakings on Standard Formula

				•		
		Net solvency capital requirement	Gross solvency capital requirement	Allocation from adjustments due to RFF and Matching adjustments portfolios	USP	Simplifications
		C0030	C0040	C0050	C0090	C0120
R0010	Market risk	17,106	46,908	0.00		
R0020	Counterparty default risk	6,997	6,997	0.00		
	Life underwriting risk	30,850	30,850	0.00		
	Health underwriting risk	,	.,,	0.00		
	Non-life underwriting risk		0	0.00		
	Diversification	-13,421	-19,974			
				•		
R0070	Intangible asset risk		0			
R0100	Basic Solvency Capital Requirement	41,532	64,782	• •		
	Calculation of Solvency Capital Requirement	C0100				
R0120	Adjustment due to RFF/MAP nSCR aggregation					
	Operational risk	1,492				
	Loss-absorbing capacity of technical provisions	-23,250				
	Loss-absorbing capacity of deferred taxes	-15,058				
	Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC					
	Solvency Capital Requirement excluding capital add-on	27,966				
	Capital add-ons already set					
	Solvency capital requirement	27,966	i			
R0410 R0420 R0430 R0440	Other information on SCR Capital requirement for duration-based equity risk sub-module Total amount of Notional Solvency Capital Requirements for remaining part Total amount of Notional Solvency Capital Requirements for ring fenced funds Total amount of Notional Solvency Capital Requirements for matching adjustment portfolios Diversification effects due to RFF nSCR aggregation for article 304  Method used to calculate the adjustment due to RFF/MAP nSCR aggregation	No adjustment				
R0460	Net future discretionary benefits	23,250				
R0590	Approach to tax rate Approach based on average tax rate	C0109 1	]			
	Calculation of loss absorbing capacity of deferred taxes	Before the shock	After the shock	CO130		
R0600	DTA	0.00				
R0610	DTA carry forward					
R0620	DTA due to deductible temporary differences					
R0630	DTL					
R0650 R0660 R0670 R0680	LAC DT  LAC DT justified by reversion of deferred tax liabilities  LAC DT justified by reference to probable future taxable economic profit  LAC DT justified by carry back, current year  LAC DT justified by carry back, future years  Maximum LAC DT			-15,058 -15,058		

Regular reporting

Article 112

	mkt	def	life	health	nl
mkt	1	0.25	0.25	0.25	0.25
def	0.25	1	0.25	0.25	0.5
life	0.25	0.25	1	0.25	0
ealth	0.25	0.25	0.25	1	0
nl	0.25	0.5	0	0	1
					TS SCR.1.32

net	gross		
26567.43	56370.1		
18985.91	26436.57		
36876.08	44326.75		
13738.23	21188.9		
7774.844	15225.51		
41532.37	64781.93		

ΣCorr x SCR

VΣCorr x SCR x SCR

### S.28.01.01

#### Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity

R0010	Linear formula component for non-life insurance and reinsurance obligations $MCR_NL$ Result	C0010 0.00			
			Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months	
R0030 R0040 R0050 R0060 R0070 R0080 R0100 R0110 R0120 R0130 R0140 R0150 R0160	Medical expense insurance and proportional reinsurance Income protection insurance and proportional reinsurance Workers' compensation insurance and proportional reinsurance Motor vehicle liability insurance and proportional reinsurance Other motor insurance and proportional reinsurance Marine, aviation and transport insurance and proportional reinsurance Fire and other damage to property insurance and proportional reinsurance General liability insurance and proportional reinsurance Credit and suretyship insurance and proportional reinsurance Legal expenses insurance and proportional reinsurance Assistance and proportional reinsurance Miscellaneous financial loss insurance and proportional reinsurance Non-proportional health reinsurance Non-proportional casualty reinsurance Non-proportional marine, aviation and transport reinsurance Non-proportional property reinsurance		C0020	C0030	α         β           4.7%         4.7%           13.1%         8.5%           10.7%         7.5%           8.5%         9.4%           7.5%         7.5%           10.3%         14.0%           9.4%         7.5%           10.3%         13.1%           17.7%         11.3%           11.3%         6.6%           18.6%         8.5%           18.6%         15.9%           18.6%         15.9%           18.6%         15.9%           18.6%         15.9%           18.6%         15.9%
R0200	Linear formula component for life insurance and reinsurance obligations $MCR_L$ Result	C0040 10,858			TS MCR.12
			Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance/SPV) total capital at risk	
R0220 R0230 R0240	Obligations with profit participation - guaranteed benefits Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations		C0050 233,113 34,899 421,715 25,337	C0060 805,086	3.7% -5.2% 0.7% 2.1% 0.07%
R0310 R0320 R0330 R0340 R0350	Overall MCR calculation Linear MCR SCR MCR cap MCR floor Combined MCR Absolute floor of the MCR Minimum Capital Requirement	10,858 27,966 12,585 6,991 10,858 3,700			13 WCA.13

 $\alpha.B + \beta.C$